section_id,chapter_id,section_number,title,title_tsv
1,4,2.3,and Chapter 1). Allostasis refers to the normal physiologic changes,1 allostasis and changes chapter normal physiologic refers the to
2,7,2.1,Racism and Child Health,and child health racism
3,7,7.68,"deaths/1,000 live births, has remained essentially unchanged for",000 1 births deaths essentially for has live remained unchanged
4,8,3.9,for Asians only; 9.4 for,4 9 asians for only
5,8,15.4,for Asians only; 48.1,1 48 asians for only
6,8,82.0,for Asian alone; 161.4,161 4 alone asian for
7,11,3.2,for neonatal and child health: All-­cause and cause-­specific mortality findings from the Global Burden of Disease Study 2019. Lancet.,2019 all and burden cause child disease findings for from global health lancet mortality neonatal of specific study the
8,12,3.4,and 3.5). Growth of economies during the first half of the 20th,20th 3 5 and during economies first growth half of the
9,12,2.77,pediatric deaths/1 million children in LMICs compared to 1.32/,1 32 children compared deaths in lmics million pediatric to
10,20,3.0,model uses the concept of the “patient journey” to describe a,a concept describe journey model of patient the to uses
11,22,5.2,describes proximal metrics to arrest and the types of code events used,and arrest code describes events metrics of proximal the to types used
12,32,0.5,"mg/kg (15-­30 mg) IV q6h, max 24h dose 120",120 15 24h 30 dose iv kg max mg q6h
13,32,0.3,mg/kg PO q4h if <50 kg,50 if kg mg po q4h
14,32,0.1,mg/kg PO q4h if <50 kg,50 if kg mg po q4h
15,32,0.05,mg/kg PO q4h if <50 kg,50 if kg mg po q4h
16,32,0.015,mg/kg IV q2-­4h,4h iv kg mg q2
17,32,0.5,mg/kg PO at bedtime (max 150 mg/day).,150 at bedtime day kg max mg po
18,32,0.1,mg/kg PO q4h prn*†,kg mg po prn q4h
19,32,1.5,"mg patch, change q72h (for children >8-­12 yr",12 8 change children for mg patch q72h yr
20,33,0.15,mg/kg dose IV/PO q8h prn. No single IV,dose iv kg mg no po prn q8h single
21,33,0.1,mg/kg/dose tid PO/IV; max dose 10 mg/day,10 day dose iv kg max mg po tid
22,33,0.01,mg/kg PO tid prn for acute onset:,acute for kg mg onset po prn tid
23,33,0.025,mg/kg in 1 hr prn,1 hr in kg mg prn
24,33,0.3,"mg/kg/dose (2.5-­5 mg) titrated as needed, up",2 5 as dose kg mg needed titrated up
25,33,0.02,mg/kg (1.5 mg) IV q6h PRN,1 5 iv kg mg prn q6h
26,33,0.1,mg/kg IV/PO/SL/PR repeat q10min × 2,2 iv kg mg po pr q10min repeat sl
27,33,0.1,mg/kg IV/PO q6h (max 5 mg/dose if <5 yr;,5 dose if iv kg max mg po q6h yr
28,39,11.1,"list suggested screening tests for infectious diseases for international adoptees or immigrants/refugees, respectively. Table 11.2 lists",11 2 adoptees diseases for immigrants infectious international list lists or refugees respectively screening suggested table tests
29,49,15.1,"Bullying, Cyberbullying, and School",and bullying cyberbullying school
30,49,15.2,Media Violence,media violence
31,51,15.3,Effects of War on Children,children effects of on war
32,59,17.1,Sexual Abuse,abuse sexual
33,62,17.2,Factitious Disorder ­Imposed on,disorder factitious imposed on
34,69,94.9,102.0,0 102
35,71,20.3,"and 20.4) (see Chapters 25 and 26). In addition, parents should",20 25 26 4 addition and chapters in parents see should
36,76,23.1,Infant Crying and Colic,and colic crying infant
37,111,52.3,mg/10.4 mg),10 4 mg
38,111,26.1,/5.2,2 5
39,111,26.1,/5.2-52.3/10.4,10 2 3 4 5 52
40,112,2.5,twice daily,daily twice
41,112,0.05,mg/kg/day,day kg mg
42,118,36.1,Rumination Disorder,disorder rumination
43,119,36.2,Pica,pica
44,119,37.1,Tic Disorders,disorders tic
45,121,37.2,Stereotypic Movement Disorder,disorder movement stereotypic
46,125,39.1,Depressive Disorders,depressive disorders
47,128,39.2,Bipolar Disorders,bipolar disorders
48,142,47.1,Schizophrenia Spectrum Disorders,disorders schizophrenia spectrum
49,145,47.3,Catatonia in Children and Adolescents,adolescents and catatonia children in
50,145,47.2,Non-Schizophrenia Spectrum Psychotic,non psychotic schizophrenia spectrum
51,146,47.4,Hallucinations of Childhood,childhood hallucinations of
52,155,314.01,"Attention-­deficit/hyperactivity disorder, combined presentation:",attention combined deficit disorder hyperactivity presentation
53,155,314.00,"Attention-­deficit/hyperactivity disorder, predominantly",attention deficit disorder hyperactivity predominantly
54,155,314.01,"Attention-­deficit/hyperactivity disorder, predominantly",attention deficit disorder hyperactivity predominantly
55,159,52.1,Math Disabilities,disabilities math
56,161,315.2,(F81.81) With impairment in written expression:,81 expression f81 impairment in with written
57,161,52.2,Writing Disabilities,disabilities writing
58,167,53.1,Childhood-­Onset Fluency Disorder,childhood disorder fluency onset
59,174,56.2,IV Genetic,genetic iv
60,194,60.5,and 60.6).,6 60 and
61,210,691.6,and Table 691.3).,3 691 and table
62,223,695.1,Erythema Multiforme,erythema multiforme
63,224,695.2,Reactive Infectious Mucocutaneous,infectious mucocutaneous reactive
64,224,695.3,Stevens-­Johnson Syndrome,johnson stevens syndrome
65,225,695.4,Toxic Epidermal Necrolysis,epidermal necrolysis toxic
66,226,695.5,Mechanobullous Disorders,disorders mechanobullous
67,227,695.7,and 695.8). The blister is subepidermal in all types of DEB. The,695 8 all and blister deb in is of subepidermal the types
68,228,695.6,Pemphigus,pemphigus
69,228,695.7,Dermatitis Herpetiformis,dermatitis herpetiformis
70,228,695.8,Linear Immunoglobulin A (IgA),a iga immunoglobulin linear
71,229,696.1,Contact Dermatitis,contact dermatitis
72,230,696.2,Nummular Eczema,eczema nummular
73,230,696.3,Pityriasis Alba,alba pityriasis
74,231,696.4,Lichen Simplex Chronicus,chronicus lichen simplex
75,231,696.5,Acute Palmoplantar Eczema,acute eczema palmoplantar
76,231,696.6,Seborrheic Dermatitis,dermatitis seborrheic
77,234,698.1,Psoriasis,psoriasis
78,236,0.4,mg/kg,kg mg
79,236,698.2,Pityriasis Lichenoides,lichenoides pityriasis
80,237,698.3,Keratosis Pilaris,keratosis pilaris
81,237,698.4,Lichen Spinulosus,lichen spinulosus
82,237,698.5,Pityriasis Rosea,pityriasis rosea
83,238,698.6,Pityriasis Rubra Pilaris,pilaris pityriasis rubra
84,238,698.7,Darier Disease (Keratosis Follicularis),darier disease follicularis keratosis
85,238,698.9,Lichen Striatus,lichen striatus
86,238,698.8,Lichen Nitidus,lichen nitidus
87,239,698.10,Lichen Planus,lichen planus
88,239,698.11,Porokeratosis,porokeratosis
89,239,698.12,Gianotti-­Crosti Syndrome (Papular,crosti gianotti papular syndrome
90,239,698.13,Acanthosis Nigricans,acanthosis nigricans
91,248,700.1,Mast Cell Activation Syndrome,activation cell mast syndrome
92,250,701.1,Panniculitis and Erythema Nodosum,and erythema nodosum panniculitis
93,251,0.5,"mg/kg 3 times a day, maximum 10 mg/dose) may be used in severe",10 3 a be day dose in kg maximum may mg severe times used
94,251,701.2,Lipodystrophy,lipodystrophy
95,260,706.1,Impetigo,impetigo
96,261,706.2,Subcutaneous Tissue Infections,infections subcutaneous tissue
97,262,706.3,Staphylococcal Scalded Skin,scalded skin staphylococcal
98,262,706.4,Ecthyma,ecthyma
99,262,706.5,Other Cutaneous Bacterial Infections,bacterial cutaneous infections other
100,270,709.1,Arthropod Bites,arthropod bites
101,271,709.2,Scabies,scabies
102,273,709.3,Pediculosis,pediculosis
103,274,709.4,Seabather’s Eruption,eruption s seabather
104,282,0.8,(0.8),0 8
105,282,1.2,(1.4),1 4
106,282,0.9,(1.1),1
107,282,0.22,Ulna,ulna
108,282,0.25,Radius,radius
109,282,0.75,Radius,radius
110,282,0.9,Ulna,ulna
111,282,0.7,(0.8),0 8
112,285,715.1,Metatarsus Adductus,adductus metatarsus
113,285,715.2,Calcaneovalgus Feet,calcaneovalgus feet
114,285,715.3,Talipes Equinovarus (Clubfoot),clubfoot equinovarus talipes
115,286,715.4,Congenital Vertical Talus,congenital talus vertical
116,287,715.5,Hypermobile Pes Planus (Flexible,flexible hypermobile pes planus
117,287,715.6,Tarsal Coalition,coalition tarsal
118,288,715.7,Cavus Feet,cavus feet
119,288,715.8,Osteochondroses/Apophysitis,apophysitis osteochondroses
120,288,715.9,Puncture Wounds of the Foot,foot of puncture the wounds
121,288,715.10,Toe Deformities,deformities toe
122,290,715.11,Painful Foot,foot painful
123,290,715.12,Shoes,shoes
124,290,716.1,Normal Limb Development,development limb normal
125,290,716.2,Limb Evaluation,evaluation limb
126,290,716.3,Torsional Deformities,deformities torsional
127,292,716.4,Coronal Plane Deformities,coronal deformities plane
128,292,716.5,Congenital Angular Deformities of,angular congenital deformities of
129,296,718.1,Discoid Lateral Meniscus,discoid lateral meniscus
130,297,718.2,Popliteal Cysts (Baker Cysts),baker cysts popliteal
131,297,718.3,Juvenile Osteochondritis Dissecans,dissecans juvenile osteochondritis
132,297,718.4,Osgood-­Schlatter Disease and,and disease osgood schlatter
133,298,718.5,Patellofemoral Pain Syndrome,pain patellofemoral syndrome
134,298,718.6,Patellofemoral Instability,instability patellofemoral
135,299,718.7,Anterior Cruciate Ligament Rupture,anterior cruciate ligament rupture
136,300,719.1,Developmental Dysplasia of the Hip,developmental dysplasia hip of the
137,302,719.2,Transient Monoarticular Synovitis,monoarticular synovitis transient
138,303,719.3,Legg-­Calvé-­Perthes Disease,calvé disease legg perthes
139,304,719.4,Slipped Capital Femoral Epiphysis,capital epiphysis femoral slipped
140,305,720.1,Idiopathic Scoliosis,idiopathic scoliosis
141,308,720.2,Congenital Scoliosis,congenital scoliosis
142,308,720.3,"Neuromuscular Scoliosis, Genetic",genetic neuromuscular scoliosis
143,309,720.4,Kyphosis,kyphosis
144,310,720.5,Back Pain in Children,back children in pain
145,311,720.6,Spondylolysis and Spondylolisthesis,and spondylolisthesis spondylolysis
146,312,720.7,Spine Infection,infection spine
147,312,720.13,and 720.14).,14 720 and
148,312,720.8,Intervertebral Disk Herniation/,disk herniation intervertebral
149,313,720.9,Tumors,tumors
150,313,721.1,Torticollis,torticollis
151,314,721.2,Klippel-­Feil Syndrome,feil klippel syndrome
152,315,721.3,Cervical Anomalies and Instabilities,and anomalies cervical instabilities
153,322,724.1,Unique Characteristics of Pediatric,characteristics of pediatric unique
154,323,724.2,Pediatric Fracture Patterns,fracture patterns pediatric
155,324,724.3,Upper Extremity Fractures,extremity fractures upper
156,325,724.4,Lower Extremity Fractures,extremity fractures lower
157,326,724.5,Operative Treatment of Fractures,fractures of operative treatment
158,326,724.6,Complications of Fractures in Children,children complications fractures in of
159,334,728.1,Growth Plate Injuries,growth injuries plate
160,334,728.2,Shoulder Injuries,injuries shoulder
161,336,728.3,Elbow Injuries,elbow injuries
162,337,728.4,Low Back Injuries,back injuries low
163,338,728.5,Hip and Pelvis Injuries,and hip injuries pelvis
164,338,728.6,Knee Injuries,injuries knee
165,339,728.7,Lower Leg Exertional Pain: Shin,exertional leg lower pain shin
166,340,728.8,Ankle Injuries,ankle injuries
167,341,728.9,Foot Injuries,foot injuries
168,369,744.1,"Complex connective tissue macroenvironment illustrated by intermingled collagen and elastin fibers, nerves, mast cells, and",and by cells collagen complex connective elastin fibers illustrated intermingled macroenvironment mast nerves tissue
169,392,1.2,Gy (120 rads),120 gy rads
170,396,759.1,Tobacco,tobacco
171,397,759.2,Marijuana Smoke Exposure,exposure marijuana smoke
172,398,12.84,(±10.6),10 6
173,398,11.19,(±5.73),5 73
174,398,8.86,(±4.60),4 60
175,398,9.18,(±4.95),4 95
176,398,8.00,(±4.65),4 65
177,398,7.07,(±3.36),3 36
178,398,6.68,(±3.42),3 42
179,399,74.9,Da,da
180,399,200.59,Da,da
181,401,0.25,point higher. A randomized placebo-­controlled treatment study,a controlled higher placebo point randomized study treatment
182,403,762.1,Mushroom Poisoning,mushroom poisoning
183,404,762.2,Solanine Poisoning,poisoning solanine
184,404,762.3,Seafood Poisoning,poisoning seafood
185,405,762.4,Melamine Poisoning,melamine poisoning
186,408,4.4,mg/kg/day PO,day kg mg po
187,412,12.5,mg/kg per dose four times daily,daily dose four kg mg per times
188,420,0.69,× 50,50
189,420,0.69,× 50 + (0.004 × 50),0 004 50
190,420,0.996,× 50,50
191,420,0.996,× 50 + (0.31 × 50),0 31 50
192,424,0.78,± 0.37% of total Hb,0 37 hb of total
193,424,0.0078,± 0.0037 (mass fraction),0 0037 fraction mass
194,424,4.5,mmol/L,l mmol
195,425,0.076,±,
196,425,0.026,mmol/L,l mmol
197,425,0.076,± 0.026 mmol/L,0 026 l mmol
198,440,64.3,and see Table 62.6). Tanner staging cannot be used as a marker,6 62 a and as be cannot marker see staging table tanner used
199,442,7.7,"kcal/mL; does not mix well, can administer as small bolus.",administer as bolus can does kcal mix ml not small well
200,442,3.3,kcal/mL can be added to milk or nutritional supplements.,added be can kcal milk ml nutritional or supplements to
201,447,7.5,mg/46 mg,46 mg
202,449,1.33,"μmol/L in males and females, respectively, ages 9-­13; and 1.71",1 13 71 9 ages and females in l males respectively μmol
203,451,0.4,mg/day,day mg
204,451,0.4,mg/day,day mg
205,451,0.4,mg/day,day mg
206,452,67.1,Thiamine (Vitamin B1),b1 thiamine vitamin
207,453,67.2,Riboflavin (Vitamin B2),b2 riboflavin vitamin
208,454,67.3,Niacin (Vitamin B3),b3 niacin vitamin
209,455,67.4,Vitamin B6 (Pyridoxine),b6 pyridoxine vitamin
210,455,67.5,Biotin,biotin
211,455,67.6,Folate,folate
212,456,67.7,Vitamin B12 (Cobalamin),b12 cobalamin vitamin
213,464,73.1,Composition of Body Fluids,body composition fluids of
214,465,73.2,Regulation of Osmolality and Volume,and of osmolality regulation volume
215,466,73.3,Sodium,sodium
216,470,73.4,Potassium,potassium
217,473,73.5,Magnesium,magnesium
218,473,1.9,"mEq/L; 0.62-­0.94 mmol/L), with some variation among clinical",0 62 94 among clinical l meq mmol some variation with
219,475,73.6,Phosphorus,phosphorus
220,477,73.7,Acid-­Base Balance,acid balance base
221,486,0.2,normal saline,normal saline
222,492,77.1,Interfacility Transport of the Seriously,interfacility of seriously the transport
223,493,77.2,Risk Adjustment and Outcomes,adjustment and outcomes risk
224,494,77.3,Principles Applicable to the,applicable principles the to
225,503,0.01,mg/kg (0.1 mL/kg of the,0 1 kg mg ml of the
226,503,0.1,mg/mL concentration).,concentration mg ml
227,503,0.1,mg/kg (0.1 mL/kg of the,0 1 kg mg ml of the
228,503,0.02,mg/kg. May repeat once.,kg may mg once repeat
229,503,0.2,mg/kg rapid bolus,bolus kg mg rapid
230,504,0.1,mg/kg (max dose: 6 mg),6 dose kg max mg
231,505,0.01,mg/kg (0.1 mL/kg of the,0 1 kg mg ml of the
232,505,0.1,mg/mL concentration).,concentration mg ml
233,520,84.1,Postural Tachycardia Syndrome,postural syndrome tachycardia
234,520,0.5,2.0 4.0 6.0 8.0 10.0 12.0 14.0 16.0 18.0 20.022.024.026.0 29.0,0 022 024 026 10 12 14 16 18 2 20 29 4 6 8
235,520,0.5,2.0 4.0 6.0 8.0 10.0 12.0 14.0 16.0 18.0 20.022.024.026.0 29.0,0 022 024 026 10 12 14 16 18 2 20 29 4 6 8
236,520,0.5,2.0 4.0 6.0 8.0 10.0 12.0 14.0 16.0 18.0 20.022.024.026.0 29.0,0 022 024 026 10 12 14 16 18 2 20 29 4 6 8
237,520,0.5,5.0 10.0 15.0 20.0 25.0 30.0 35.0 40.0 45.0 50.0 55.0 60.0,0 10 15 20 25 30 35 40 45 5 50 55 60
238,520,0.5,5.0 10.0 15.0 20.0 25.0 30.0 35.0 40.0 45.0 50.0 55.0 60.0,0 10 15 20 25 30 35 40 45 5 50 55 60
239,520,0.5,5.0 10.0 15.0 20.0 25.0 30.0 35.0 40.0 45.0 50.0 55.0 60.0,0 10 15 20 25 30 35 40 45 5 50 55 60
240,520,35.0,37.0,0 37
241,520,35.0,37.0,0 37
242,520,35.0,37.0,0 37
243,527,6.0,L/min/m2 is appropriate.,appropriate is l m2 min
244,530,0.03,for every 10 mm Hg rise in Paco2. Thus an infant with bronchopulmonary dysplasia who has a basal Paco2 of 60 mm Hg will have a,10 60 a an basal bronchopulmonary dysplasia every for has have hg in infant mm of paco2 rise thus who will with
245,530,0.95,(Table 86.9). When supplemental oxygen alone is inadequate to,86 9 alone inadequate is oxygen supplemental table to when
246,531,0.1,mg/kg IV,iv kg mg
247,531,0.1,mg/kg IV,iv kg mg
248,531,0.1,mg/kg IV,iv kg mg
249,531,0.1,mg/kg IV,iv kg mg
250,531,0.1,mg/kg IV,iv kg mg
251,531,86.1,Mechanical Ventilation,mechanical ventilation
252,534,0.5,seconds) time in the CPAPLOW phase. These atypically long Tis are tolerated because of a floating expiratory valve in the ventilator circuit that,a are atypically because circuit cpaplow expiratory floating in long of phase seconds that the these time tis tolerated valve ventilator
253,538,2.5,mg/kg PO every 12 hours;,12 every hours kg mg po
254,538,1.25,mg/kg PO every 12 hours;,12 every hours kg mg po
255,538,0.15,mg/kg PO/IM/IV every 6 hours;,6 every hours im iv kg mg po
256,549,89.1,Lightning Burns,burns lightning
257,550,14.2,(57.6),57 6
258,550,13.7,(56.7),56 7
259,552,90.1,Cold-­Induced Autoinflammatory and,and autoinflammatory cold induced
260,554,91.6,"lists preoperative fasting guidelines (e.g., nothing by mouth, or nil",by e fasting g guidelines lists mouth nil nothing or preoperative
261,559,91.1,Anesthetic Neurotoxicity,anesthetic neurotoxicity
262,562,1.5,mg,mg
263,562,0.15,mg/kg,kg mg
264,562,0.2,mg,mg
265,562,0.6,mg,mg
266,562,0.01,mg q2-­4h,4h mg q2
267,562,0.002,mg/kg/hr,hr kg mg
268,562,0.01,mg q2-­4h,4h mg q2
269,562,0.002,mg/kg/hr,hr kg mg
270,562,0.1,mg/kg q8-­24h,24h kg mg q8
271,562,0.1,mg/kg q8-­24h,24h kg mg q8
272,562,0.2,mg/kg q8-­12h,12h kg mg q8
273,562,2.5,mg TID,mg tid
274,562,0.05,mg/kg q2-­4h,4h kg mg q2
275,562,0.1,mg/kg q2-­4h,4h kg mg q2
276,562,0.3,mg/kg q3-­4h,4h kg mg q3
277,564,0.8,(sublingual),sublingual
278,564,93.15,and 93.16).,16 93 and
279,564,93.4,presents a decision-­making tree to help the physician select the,a decision help making physician presents select the to tree
280,566,2.5,mg/kg per day divided bid or tid,bid day divided kg mg or per tid
281,575,0.02,mg/kg over 5 min; may repeat q5-­10 min,10 5 kg may mg min over q5 repeat
282,575,0.2,"mg over 30 sec; if response is inadequate,",30 if inadequate is mg over response sec
283,575,0.15,mg/kg bolus followed by infusion of,bolus by followed infusion kg mg of
284,597,98.3,Thiopurine S-­methyltransferase,methyltransferase s thiopurine
285,598,98.1,Genetic Counseling,counseling genetic
286,599,98.2,Principles of Management and,and management of principles
287,601,99.1,Methods of Chromosome Analysis,analysis chromosome methods of
288,602,99.6,and 99.7). Oligonucleotides (short DNA segments) encompassing,7 99 and dna encompassing oligonucleotides segments short
289,603,99.2,Abnormalities of Chromosome Number,abnormalities chromosome number of
290,604,99.3,Abnormalities of Chromosome,abnormalities chromosome of
291,606,99.4,Sex Chromosome Aneuploidy,aneuploidy chromosome sex
292,607,99.5,Mosaicism,mosaicism
293,608,99.6,Chromosome Instability Syndromes,chromosome instability syndromes
294,608,99.7,Uniparental Disomy and Imprinting,and disomy imprinting uniparental
295,610,99.13,and 99.14). Imprinting probably occurs in many different parts of,14 99 and different imprinting in many occurs of parts probably
296,616,101.1,RAS/MAPK Pathway,mapk pathway ras
297,617,101.2,Sonic Hedgehog Pathway,hedgehog pathway sonic
298,618,101.3,Ciliopathies,ciliopathies
299,619,101.4,Craniosynostoses,craniosynostoses
300,622,103.1,Major Genetic Approaches to the,approaches genetic major the to
301,625,104.13,and Fig. 104.2). Elevation of blood ammonia is usually caused,104 2 ammonia and blood caused elevation fig is of usually
302,627,105.1,Phenylalanine,phenylalanine
303,629,105.2,Tyrosine,tyrosine
304,631,105.3,Methionine,methionine
305,633,105.4,Cysteine and Cystine,and cysteine cystine
306,633,105.5,Tryptophan,tryptophan
307,634,105.6,"Isoleucine, Leucine, Valine, and",and isoleucine leucine valine
308,640,105.7,Glycine,glycine
309,641,105.8,Serine Deficiency Disorders (Serine,deficiency disorders serine
310,642,105.8,and 105.10 show the metabolic pathway for the synthesis and,10 105 and for metabolic pathway show synthesis the
311,642,105.9,Proline,proline
312,642,105.10,Glutamic Acid,acid glutamic
313,643,105.11,Disorders of Neurotransmitter,disorders neurotransmitter of
314,644,105.1,"and Fig. 105.12), but because of the low activity of dihydrofolate reductase in the brain, the amount of BH4 remains insufficient for",105 12 activity amount and because bh4 brain but dihydrofolate fig for in insufficient low of reductase remains the
315,645,105.12,Urea Cycle and Hyperammonemia,and cycle hyperammonemia urea
316,648,105.13,Histidine,histidine
317,649,105.14,Lysine,lysine
318,649,105.9,and Fig. 105.9).,105 9 and fig
319,649,611.04,and 611.06).,06 611 and
320,650,105.15,N-­Acetylaspartic Acid (Canavan,acetylaspartic acid canavan n
321,651,106.1,Disorders of Mitochondrial Fatty Acid,acid disorders fatty mitochondrial of
322,654,106.2,Disorders of Very Long Chain,chain disorders long of very
323,657,106.3,Disorders of Lipoprotein Metabolism,disorders lipoprotein metabolism of
324,663,106.4,Lipidoses (Lysosomal Storage,lipidoses lysosomal storage
325,668,1.0,yr,yr
326,668,2.0,yr,yr
327,668,2.0,yr,yr
328,668,2.5,yr,yr
329,668,2.5,yr,yr
330,668,3.5,yr,yr
331,668,4.0,yr,yr
332,668,4.0,yr,yr
333,668,4.0,yr,yr
334,668,4.0,yr,yr
335,668,4.0,yr,yr
336,668,4.4,yr,yr
337,670,106.5,Mucolipidoses,mucolipidoses
338,670,107.1,Glycogen Storage Diseases,diseases glycogen storage
339,675,107.2,Defects in Galactose Metabolism,defects galactose in metabolism
340,676,107.3,Defects in Fructose Metabolism,defects fructose in metabolism
341,677,107.4,Defects in Intermediary Carbohydrate,carbohydrate defects in intermediary
342,680,107.5,Defects in Pentose Metabolism,defects in metabolism pentose
343,680,107.6,Disorders of Glycoprotein,disorders glycoprotein of
344,681,107.7,Congenital Disorders of Glycosylation,congenital disorders glycosylation of
345,684,1.5,g/kg/day (up to 3,3 day g kg to up
346,714,0.3,mg/kg/wk daily or every 12 hr (infants),12 daily every hr infants kg mg or wk
347,716,117.7,Treatment and Prevention of Fetal,and fetal of prevention treatment
348,722,119.1,Multiple-­Gestation Pregnancies,gestation multiple pregnancies
349,723,119.2,Extremely and Very Preterm Infants,and extremely infants preterm very
350,725,119.3,Moderate and Late Preterm Infants,and infants late moderate preterm
351,726,119.4,Term and Postterm Infants,and infants postterm term
352,727,119.5,Follow-­Up of High-­Risk Infants After,after follow high infants of risk up
353,727,119.10,lists common sequelae of prematurity.,common lists of prematurity sequelae
354,730,121.2,Hypothermia and Cold Stress,and cold hypothermia stress
355,730,121.1,Hyperthermia,hyperthermia
356,730,121.3,Edema,edema
357,730,121.4,Hypocalcemia,hypocalcemia
358,730,121.5,Hypermagnesemia,hypermagnesemia
359,730,122.1,The Cranium,cranium the
360,731,122.2,Neonatal Traumatic Head Injuries,head injuries neonatal traumatic
361,731,122.3,Intracranial-­Intraventricular,intracranial intraventricular
362,733,122.4,Hypoxic-­Ischemic Encephalopathy,encephalopathy hypoxic ischemic
363,734,122.7,and 122.8). Cerebral edema may develop during the next 24,122 24 8 and cerebral develop during edema may next the
364,736,122.5,Spine and Spinal Cord,and cord spinal spine
365,736,122.6,Peripheral Nerve Injuries,injuries nerve peripheral
366,736,4.6,"per 1,000 live births. Injury to the brachial plexus may cause paralysis of the upper part of the arm with or without paralysis of the forearm",000 1 arm births brachial cause forearm injury live may of or paralysis part per plexus the to upper with without
367,743,126.1,Patent Ductus Arteriosus,arteriosus ductus patent
368,750,131.1,Foramen of Morgagni Hernia,foramen hernia morgagni of
369,750,131.2,Paraesophageal Hernia,hernia paraesophageal
370,750,131.3,Eventration,eventration
371,759,137.1,Kernicterus and Therapy of,and kernicterus of therapy
372,764,0.2,"per 1,000 births, respectively. Clinical signs of FMH vary due to",000 1 births clinical due fmh of per respectively signs to vary
373,764,11.0,(33%),33
374,764,10.0,(30%),30
375,764,10.0,(30%),30
376,764,8.5,(25%),25
377,764,8.5,(25%),25
378,764,7.0,(21%),21
379,766,138.2,and 139.1). Full-­term infants are therefore considered polycythemic,1 139 and are considered full infants polycythemic term therefore
380,766,138.2,and 139.1). Full-­term infants are therefore considered polycythemic,1 139 and are considered full infants polycythemic term therefore
381,770,0.05,mg/kg/dose q3h,dose kg mg q3h
382,770,0.1,mg/kg/dose q6h for,dose for kg mg q6h
383,770,0.7,"mg/kg/dose q12h × 2 doses,",2 dose doses kg mg q12h
384,770,0.04,mg/kg/dose q12h × 2,2 dose kg mg q12h
385,770,0.03,mg/kg/dose q12h × 2,2 dose kg mg q12h
386,770,0.02,mg/kg/dose q12h × 2,2 dose kg mg q12h
387,770,0.01,mg/kg/dose q12h × 2,2 dose kg mg q12h
388,770,0.01,mg/kg/dose q24h × 1,1 dose kg mg q24h
389,770,1.5,μg/kg/dose q3h,dose kg q3h μg
390,775,13.5,(12.5-­14.6),12 14 5 6
391,775,45.4,(38.3-­53.7),3 38 53 7
392,775,26.0,(22.6-­29.9),22 29 6 9
393,775,15.5,(13.2-­18.2),13 18 2
394,775,10.1,(8.5-­11.9),11 5 8 9
395,776,148.1,"and 148.5); (3) premature infants have documented immune dysfunction; and (4) premature infants often require prolonged intravenous access, endotracheal intubation, or other invasive procedures that",148 3 4 5 access and documented dysfunction endotracheal have immune infants intravenous intubation invasive often or other premature procedures prolonged require that
396,779,149.1,Congenital Infections,congenital infections
397,780,149.2,Perinatal Infections,infections perinatal
398,782,149.7,provides a summary of laboratory tests that are useful to diagnose specific perinatal infections.,a are diagnose infections laboratory of perinatal provides specific summary tests that to useful
399,783,8.8,years in Black females and 9.6 years in White females. Almost 25%,25 6 9 almost and black females in white years
400,787,151.1,Legal Issues,issues legal
401,788,151.2,Screening Procedures,procedures screening
402,791,22.5,mg,mg
403,791,153.6,and 153.7).,153 7 and
404,792,12.5,μg/24 hr every,24 every hr μg
405,792,12.5,mg/m2 every,every m2 mg
406,792,37.5,mg every 6 mo,6 every mg mo
407,799,6.1,(1.1-­33.83),1 33 83
408,799,5.8,(1.7-­19.2),1 19 2 7
409,799,10.7,(3.2-­35.6),2 3 35 6
410,799,4.6,(1.5-­14.2),1 14 2 5
411,799,2.1,(0.72-­6.2),0 2 6 72
412,799,8.6,(1.4-­54.2),1 2 4 54
413,799,0.85,(0.19-­3.8),0 19 3 8
414,799,4.6,(0.93-­23.0),0 23 93
415,799,3.0,(0.88-­10.3),0 10 3 88
416,799,0.83,(0.08-­8.5),0 08 5 8
417,799,6.4,(1.3-­30.7),1 3 30 7
418,799,3.7,(0.93-­14.4),0 14 4 93
419,799,4.3,(1.1-­17.6),1 17 6
420,799,24.6,(4.3-­138.7),138 3 4 7
421,799,6.1,(1.6-­22),1 22 6
422,799,6.2,(1.1-­34.2),1 2 34
423,799,3.6,(1.1-­11.7),1 11 7
424,801,157.1,Alcohol,alcohol
425,802,157.2,"Tobacco, E-­Cigarettes, and Other",and cigarettes e other tobacco
426,803,0.5,mg PO in morning for 3 days; increase to,3 days for in increase mg morning po to
427,803,0.5,"mg PO bid for 4 days, then increase to",4 bid days for increase mg po then to
428,803,0.5,mg/spray,mg spray
429,803,157.3,Marijuana,marijuana
430,803,157.4,Inhalants,inhalants
431,804,157.5,EVALI,evali
432,804,157.6,Hallucinogens,hallucinogens
433,805,157.7,Cocaine,cocaine
434,805,157.8,Amphetamines,amphetamines
435,806,157.9,Stimulant Use and Diversion,and diversion stimulant use
436,806,157.10,Opiates/Opioids,opiates opioids
437,806,157.11,Synthetic Cannabinoids,cannabinoids synthetic
438,808,159.1,Amenorrhea,amenorrhea
439,809,159.2,Abnormal Uterine Bleeding,abnormal bleeding uterine
440,809,159.3,Dysmenorrhea,dysmenorrhea
441,810,11.25,mg IM q3mo,im mg q3mo
442,810,159.4,Premenstrual Syndrome and,and premenstrual syndrome
443,811,160.1,Contraceptive Use,contraceptive use
444,812,160.2,Contraceptive Counseling,contraceptive counseling
445,812,160.3,Long-­Acting Reversible Contraception,acting contraception long reversible
446,813,160.4,Other Progestin-­Only Methods,methods only other progestin
447,813,17.5,mcg LNG/day → 7.4,4 7 day lng mcg
448,813,19.5,mcg LNG/day → 9.8,8 9 day lng mcg
449,813,4.4,mm,mm
450,813,3.8,mm diameter,diameter mm
451,813,4.4,mm diameter,diameter mm
452,813,3.8,mm diameter,diameter mm
453,813,160.5,Combined Hormonal Contraceptives,combined contraceptives hormonal
454,815,160.6,Emergency Contraception,contraception emergency
455,816,160.7,Condoms,condoms
456,816,160.8,Other Barrier Methods,barrier methods other
457,816,160.9,Other Contraceptive Methods,contraceptive methods other
458,818,161.1,Abortion,abortion
459,822,11.7,10–14 83.1,1 10 14 83
460,822,114.9,45–54 73.7,45 54 7 73
461,822,46.9,55–64 20.1,1 20 55 64
462,822,7.9,65+ 2.5,2 5 65
463,822,0.0,10–14 0.2,0 10 14 2
464,832,165.1,Severe Combined Immunodeficiencies,combined immunodeficiencies severe
465,834,165.2,Combined Immunodeficiencies,combined immunodeficiencies
466,839,165.3,Thymic Disorders,disorders thymic
467,839,165.4,Inborn Errors of Immunity with a,a errors immunity inborn of with
468,840,166.1,Agammaglobulinemia,agammaglobulinemia
469,841,166.2,"Hypogammaglobulinemia, Transient",hypogammaglobulinemia transient
470,843,166.3,Class Switch Defects,class defects switch
471,844,166.4,Isotype Defects,defects isotype
472,844,166.5,Transient Hypogammaglobulinemia of,hypogammaglobulinemia of transient
473,846,6.5,× 108 cells/kg,108 cells kg
474,846,3.2,× 108 cells/kg,108 cells kg
475,846,3.3,× 108 cells/kg,108 cells kg
476,846,1.8,× 108 cells/kg,108 cells kg
477,846,1.8,× 107 cells/kg,107 cells kg
478,846,1.8,× 109 cells/kg,109 cells kg
479,859,173.1,"Complement Components, Pathways,",complement components pathways
480,859,173.1,"and 173.2). It represents an essential part of immunity, having a",173 2 a an and essential having immunity it of part represents
481,860,173.2,Complement Pathway Deficiencies,complement deficiencies pathway
482,863,174.1,Tregopathies,tregopathies
483,864,174.2,Hemophagocytic Lymphohistiocytosis,hemophagocytic lymphohistiocytosis
484,864,174.3,Epstein-­Barr Virus Susceptibility,barr epstein susceptibility virus
485,865,174.4,Chronic Active Epstein-­Barr Virus,active barr chronic epstein virus
486,866,174.6,Autoimmune Cytopenias,autoimmune cytopenias
487,866,174.5,Very Early Onset Inflammatory Bowel,bowel early inflammatory onset very
488,867,174.7,Autoimmune Lymphoproliferative,autoimmune lymphoproliferative
489,868,174.8,Nuclear Factor-­κB Pathway Defects,defects factor nuclear pathway κb
490,869,175.1,Predisposition to Fungal Infections,fungal infections predisposition to
491,870,175.2,Innate Immunity Defects with,defects immunity innate with
492,871,175.3,Susceptibility to Invasive Bacterial,bacterial invasive susceptibility to
493,872,175.4,Mendelian Susceptibility to,mendelian susceptibility to
494,892,184.1,"and Fig. 184.2). Occupational risks for rhinitis include exposure to allergens (grain dust, insects, latex, enzymes) and irritants",184 2 allergens and dust enzymes exposure fig for grain include insects irritants latex occupational rhinitis risks to
495,893,2.5,"mg, 5 mg",5 mg
496,893,0.5,mg/mL,mg ml
497,894,0.5,mg/mL,mg ml
498,894,0.5,mg/mL,mg ml
499,904,0.25,"mg, 0.5 mg, 1 mg",0 1 5 mg
500,904,0.5,mg,mg
501,904,1.0,mg,mg
502,904,2.0,mg,mg
503,906,1.25,"mg/3 mL, 0.63 mg/3 mL)",0 3 63 mg ml
504,906,0.63,"mg/3 mL, 1.25 mg/3 mL)",1 25 3 mg ml
505,906,0.5,mg/2.5 mL; MDI 18 μg/inhalation),18 2 5 inhalation mdi mg ml μg
506,906,0.3,"mg/kg up to 10 mg every 1-­4 hr as needed, or",1 10 4 as every hr kg mg needed or to up
507,906,0.075,mg/kg (minimum 1.25 mg) every 20 min for 3 Levalbuterol 0.63 mg is equivalent to 1.25 mg,0 1 20 25 3 63 equivalent every for is kg levalbuterol mg min minimum to
508,919,189.1,Hereditary Angioedema,angioedema hereditary
509,922,0.01,"mg/kg, up to 0.3 mg IM in lateral thigh",0 3 im in kg lateral mg thigh to up
510,922,0.1,mg for 7.5-­13 kg,13 5 7 for kg mg
511,922,0.15,mg for <25 kg,25 for kg mg
512,922,0.3,mg for 25 kg or more,25 for kg mg more or
513,922,0.25,"mg/kg, up to 10 mg PO",10 kg mg po to up
514,922,0.01,"mg/kg, up to 0.5 mg IM in lateral thigh",0 5 im in kg lateral mg thigh to up
515,922,0.1,mg for 7.5-­13 kg,13 5 7 for kg mg
516,922,0.15,mg for <25 kg,25 for kg mg
517,922,0.3,mg for 25 kg or more,25 for kg mg more or
518,922,0.01,"mL/kg/dose of 1:1,000 (vial) solution, up",000 1 dose kg ml of solution up vial
519,922,0.25,"mg/kg, up to 10 mg PO",10 kg mg po to up
520,922,1.25,"mg/kg, up to 50 mg PO, IM, or IV",50 im iv kg mg or po to up
521,922,0.83,mg/mL (3 mL) via mask with O2,3 mask mg ml o2 via with
522,927,192.1,Non-­IgE Gastrointestinal Food Allergy,allergy food gastrointestinal ige non
523,932,0.01,M,m
524,932,0.01,M,m
525,936,0.125,mg/kg PO daily,daily kg mg po
526,936,0.8,mg/kg SC once weekly (max,kg max mg once sc weekly
527,944,0.8,mg/kg SC weekly or 0.4 mg/kg SC twice,0 4 kg mg or sc twice weekly
528,944,0.125,mg/kg PO once daily (maximum dose Same as above,above as daily dose kg maximum mg once po same
529,944,2.2,mg/kg/dose SC weekly (maximum dose,dose kg maximum mg sc weekly
530,952,199.1,Neonatal Lupus,lupus neonatal
531,953,200.2,and 200.3). Certain myositis-­specific antibodies are associated,200 3 and antibodies are associated certain myositis specific
532,958,2.4,mg/dL,dl mg
533,960,201.5,"and 201.6). RP is treated with cold avoidance, and pharmacologic interventions are reserved for severe disease. Calcium channel",201 6 and are avoidance calcium channel cold disease for interventions is pharmacologic reserved rp severe treated with
534,963,12.5,years) showing evidence of,evidence of showing years
535,973,210.1,Henoch-­Schönlein Purpura,henoch purpura schönlein
536,976,210.2,Takayasu Arteritis,arteritis takayasu
537,977,210.3,Polyarteritis Nodosa and Cutaneous,and cutaneous nodosa polyarteritis
538,978,210.4,Antineutrophilic Cytoplasmic,antineutrophilic cytoplasmic
539,979,210.11,lists the classification criteria for pediatric-­onset GPA.,classification criteria for gpa lists onset pediatric the
540,980,210.5,Other Vasculitis Syndromes:,other syndromes vasculitis
541,982,211.1,Growing Pains (Benign Limb Pain of,benign growing limb of pain pains
542,982,211.2,Small Fiber Polyneuropathy,fiber polyneuropathy small
543,982,211.3,Diffuse Amplified Pain Syndromes,amplified diffuse pain syndromes
544,983,211.4,Complex Regional Pain Syndrome,complex pain regional syndrome
545,983,211.5,Erythromelalgia,erythromelalgia
546,985,212.1,Chronic Fatigue Syndrome,chronic fatigue syndrome
547,1003,215.1,International Immunization Practices,immunization international practices
548,1012,0.5,mL (720 ELISA,720 elisa ml
549,1012,1.0,"mL (1,440",1 440 ml
550,1012,0.5,mL (25 U),25 ml u
551,1012,1.0,mL (50 U),50 ml u
552,1012,0.5,mL (20 μg,20 ml μg
553,1012,0.5,mL (10 μg,10 ml μg
554,1012,0.5,mL (10 μg,10 ml μg
555,1012,0.5,mL (5 μg,5 ml μg
556,1012,1.0,mL (720 ELU,720 elu ml
557,1012,1.0,mL (720 ELU,720 elu ml
558,1012,0.25,mL,ml
559,1012,0.5,mL,ml
560,1012,0.5,mL,ml
561,1012,0.5,mL,ml
562,1012,0.5,mL,ml
563,1012,0.5,mL,ml
564,1012,0.5,mL,ml
565,1012,0.5,mL,ml
566,1013,0.5,mL,ml
567,1015,0.5,mL,ml
568,1015,0.5,mL10,ml10
569,1017,2.2,mg/kg daily (max: Known safety,daily kg known max mg safety
570,1017,62.5,mg,mg
571,1017,6.5,mg/kg of salt (5,5 kg mg of salt
572,1017,26.3,mg salt (15,15 mg salt
573,1017,0.8,mg/kg of salt,kg mg of salt
574,1017,26.3,mg salt,mg salt
575,1017,0.8,mg/kg of salt,kg mg of salt
576,1030,223.1,Infections Occurring with Primary,infections occurring primary with
577,1031,223.2,Infections Occurring with Acquired,acquired infections occurring with
578,1033,223.3,Prevention of Infection in,in infection of prevention
579,1039,12.5,mg/kg) IV q8h for 5-­14 days,14 5 days for iv kg mg q8h
580,1039,12.5,mg/kg) IV q8h for 5-­14 days; not to exceed 2.5 g,14 2 5 days exceed for g iv kg mg not q8h to
581,1042,2.4,million units/dose),dose million units
582,1042,4.8,million units/dose),dose million units
583,1042,1.9,mEq sodium. Interferes with platelet,interferes meq platelet sodium with
584,1042,1.9,mEq sodium.,meq sodium
585,1047,227.1,Staphylococcus aureus,aureus staphylococcus
586,1049,227.2,Toxic Shock Syndrome,shock syndrome toxic
587,1050,227.3,Coagulase-­Negative Staphylococci,coagulase negative staphylococci
588,1056,229.1,Rheumatic Fever,fever rheumatic
589,1077,37.8,39.2,2 39
590,1079,240.1,and Chapter 215). Available combination vaccines include Pentacel,215 and available chapter combination include pentacel vaccines
591,1083,244.1,Nontyphoidal Salmonellosis,nontyphoidal salmonellosis
592,1086,244.2,Enteric Fever (Typhoid and,and enteric fever typhoid
593,1094,0.8,"μm wide), non–spore-­forming rods (0.5-­5 μm long) that usually",0 5 forming long non rods spore that usually wide μm
594,1096,249.1,Yersinia enterocolitica,enterocolitica yersinia
595,1096,1.97,"per 100,000 population (635% increase compared to 2015, and",000 100 2015 635 and compared increase per population to
596,1097,249.2,Yersinia pseudotuberculosis,pseudotuberculosis yersinia
597,1097,249.3,Plague (Yersinia pestis),pestis plague yersinia
598,1098,7.5,"mg/kg IM or intravenously [IV] every 24 hours; adults, 5 mg/",24 5 adults every hours im intravenously iv kg mg or
599,1098,250.1,Aeromonas,aeromonas
600,1099,250.2,Plesiomonas shigelloides,plesiomonas shigelloides
601,1100,251.1,Pseudomonas aeruginosa,aeruginosa pseudomonas
602,1101,251.2,Burkholderia cepacia Complex,burkholderia cepacia complex
603,1102,251.3,Stenotrophomonas,stenotrophomonas
604,1103,252.3,displays therapeutic options for treatment of tularemia and,and displays for of options therapeutic treatment tularemia
605,1105,2.4,g/day) in 2 divided doses,2 day divided doses g in
606,1106,255.1,Cat Scratch Disease (Bartonella,bartonella cat disease scratch
607,1107,255.2,Bartonellosis (Bartonella bacilliformis),bacilliformis bartonella bartonellosis
608,1108,255.3,Trench Fever (Bartonella quintana),bartonella fever quintana trench
609,1108,255.4,Bacillary Angiomatosis and Bacillary,and angiomatosis bacillary
610,1116,1.5,mg/day PO or 800 mg/day IV. The adult dosage of ciprofloxacin,800 adult ciprofloxacin day dosage iv mg of or po the
611,1126,261.8,and 261.9). Treatment regimens should prioritize administering,261 9 administering and prioritize regimens should treatment
612,1126,2.5,g,g
613,1138,265.1,Yaws (Treponema pertenue),pertenue treponema yaws
614,1139,265.2,Bejel (Endemic Syphilis; Treponema,bejel endemic syphilis treponema
615,1139,265.3,Pinta (Treponema carateum),carateum pinta treponema
616,1143,4.4,mg/kg/day in 2 divided doses,2 day divided doses in kg mg
617,1148,272.1,Trachoma,trachoma
618,1148,272.2,Genital Tract Infections,genital infections tract
619,1148,272.3,Conjunctivitis and Pneumonia in,and conjunctivitis in pneumonia
620,1149,272.4,Lymphogranuloma Venereum,lymphogranuloma venereum
621,1150,274.1,Rocky Mountain Spotted Fever,fever mountain rocky spotted
622,1153,274.2,Mediterranean Spotted Fever or,fever mediterranean or spotted
623,1154,274.3,Rickettsialpox (Rickettsia akari) and,akari and rickettsia rickettsialpox
624,1155,276.1,Murine (Endemic or Flea-­Borne),borne endemic flea murine or
625,1155,276.2,Epidemic (Louse-­Borne) Typhus,borne epidemic louse typhus
626,1159,279.1,and 279.2).,2 279 and
627,1160,2.5,mg/kg/dose bid,bid dose kg mg
628,1160,1.5,mg/kg/day,day kg mg
629,1162,280.1,Neonatal Infections,infections neonatal
630,1162,280.2,Infections in Immunocompetent,immunocompetent in infections
631,1163,1.5,mg/kg/day,day kg mg
632,1163,280.3,Infections in Immunocompromised,immunocompromised in infections
633,1163,1.5,mg/kg/day,day kg mg
634,1166,283.1,Allergic Disease (Hypersensitivity,allergic disease hypersensitivity
635,1166,283.2,Saprophytic (Noninvasive) Syndromes,noninvasive saprophytic syndromes
636,1166,283.3,Invasive Disease,disease invasive
637,1183,0.02,mL/kg,kg ml
638,1183,0.06,mL/kg,kg ml
639,1183,0.06,mL/kg,kg ml
640,1183,0.50,mL/kg,kg ml
641,1183,0.5,mL/kg (maximum dose in both cases is 15 mL/kg) intramuscularly.,15 both cases dose in intramuscularly is kg maximum ml
642,1207,2.4,years following infectious mononucleosis. EBV is associated with,associated ebv following infectious is mononucleosis with years
643,1222,311.1,COVID-­19,19 covid
644,1223,208.4,"in Chapter 208). As of late 2023, there have been >9500 cases and",2023 208 9500 and as been cases chapter have in late of there
645,1227,1.22,(0.70-­2.15),0 15 2 70
646,1227,0.94,(0.83-­1.07),0 07 1 83
647,1227,1.23,(1.16-­1.31)†,1 16 31
648,1227,1.17,(1.12-­1.23)†,1 12 23
649,1227,1.11,(1.08-­1.13)†,08 1 13
650,1227,1.04,(1.02-­1.06)†,02 06 1
651,1227,1.13,(1.05-­1.22)†,05 1 22
652,1227,1.08,(1.05-­1.12)†,05 1 12
653,1227,1.03,(1.01-­1.04)†,01 04 1
654,1227,1.16,(1.10-­1.21)†,1 10 21
655,1227,1.06,(1.04-­1.07)†,04 07 1
656,1227,1.00,(0.99-­1.01),0 01 1 99
657,1227,1.08,(0.90-­1.29),0 1 29 90
658,1227,1.03,(0.99-­1.08),0 08 1 99
659,1227,1.00,(0.98-­1.02),0 02 1 98
660,1227,1.15,(1.10-­1.20)†,1 10 20
661,1227,1.02,(1.00-­1.04)†,00 04 1
662,1227,0.97,(0.95-­0.99)†,0 95 99
663,1227,0.99,(0.93-­1.06),0 06 1 93
664,1227,0.89,(0.86-­0.92)†,0 86 92
665,1227,0.91,(0.89-­0.94)†,0 89 94
666,1227,1.07,(1.04-­1.10)†,04 1 10
667,1227,0.93,(0.92-­0.94)†,0 92 94
668,1227,0.88,(0.87-­0.89)†,0 87 89
669,1227,1.03,(0.97-­1.10),0 1 10 97
670,1227,0.92,(0.90-­0.95)†,0 90 95
671,1227,0.89,(0.86-­0.91)†,0 86 91
672,1227,2.03,(1.61-­2.56)†,1 2 56 61
673,1227,2.39,(1.57–3.65)†,1 3 57 65
674,1227,2.84,(2.39-­3.37)†,2 3 37 39
675,1227,1.66,(1.48-­1.88)†,1 48 88
676,1227,2.69,(1.73-­4.19)†,1 19 4 73
677,1227,1.52,(1.22-­1.91)†,1 22 91
678,1227,1.52,(1.07–2.14)†,07 1 14 2
679,1227,1.38,(1.16–1.63)†,1 16 63
680,1227,1.27,(1.15–1.40)†,1 15 40
681,1227,1.01,(0.57-­1.78),0 1 57 78
682,1227,1.31,(1.13-­1.53)†,1 13 53
683,1227,1.20,(1.09–1.33)†,09 1 33
684,1227,1.47,(1.20-­1.80)†,1 20 80
685,1227,1.28,(1.15-­1.43)†,1 15 43
686,1227,1.10,(1.03–1.19)†,03 1 19
687,1227,1.24,(0.85-­1.81),0 1 81 85
688,1227,1.14,(1.02-­1.28)†,02 1 28
689,1227,1.18,(1.11-­1.24)†,1 11 24
690,1227,1.44,(1.22-­1.70)†,1 22 70
691,1227,1.23,(1.14-­1.32)†,1 14 32
692,1227,1.12,(1.08-­1.17)†,08 1 17
693,1227,1.66,(0.85-­3.23),0 23 3 85
694,1227,1.14,(0.79-­1.64),0 1 64 79
695,1227,1.18,(0.93-­1.48),0 1 48 93
696,1227,0.86,(0.54-­1.36),0 1 36 54
697,1227,1.04,(0.83-­1.31),0 1 31 83
698,1227,1.12,(0.96-­1.31),0 1 31 96
699,1227,1.12,(1.07-­1.18)†,07 1 18
700,1227,1.02,(1.00-­1.05)†,00 05 1
701,1227,0.96,(0.94-­0.98)†,0 94 98
702,1227,0.87,(0.77-­0.98)†,0 77 98
703,1227,0.86,(0.82-­0.91)†,0 82 91
704,1227,0.96,(0.93-­0.99)†,0 93 99
705,1227,0.98,(0.93-­1.04),0 04 1 93
706,1227,0.96,(0.93-­0.98)†,0 93 98
707,1227,0.91,(0.89-­0.93)†,0 89 93
708,1227,0.91,(0.83-­1.00),0 00 1 83
709,1227,0.86,(0.83-­0.88)†,0 83 88
710,1227,0.84,(0.82-­0.85)†,0 82 85
711,1227,0.82,(0.62-­1.08),0 08 1 62
712,1227,0.73,(0.69-­0.77)†,0 69 77
713,1227,0.80,(0.77-­0.83)†,0 77 83
714,1232,314.1,Eastern Equine Encephalitis,eastern encephalitis equine
715,1232,314.2,Western Equine Encephalitis,encephalitis equine western
716,1233,314.4,West Nile Encephalitis,encephalitis nile west
717,1233,314.3,St. Louis Encephalitis,encephalitis louis st
718,1233,314.5,Powassan Encephalitis,encephalitis powassan
719,1233,314.6,La Crosse and California Encephalitis,and california crosse encephalitis la
720,1233,314.7,Colorado Tick Fever,colorado fever tick
721,1233,314.8,Chikungunya Fever,chikungunya fever
722,1233,314.4,Algorithm showing,algorithm showing
723,1234,314.9,Venezuelan Equine Encephalitis,encephalitis equine venezuelan
724,1234,314.10,Japanese Encephalitis,encephalitis japanese
725,1234,314.11,Tick-­Borne Encephalitis,borne encephalitis tick
726,1235,314.12,Zika Virus,virus zika
727,1250,322.7,"for definitions of low and high risk. *For higher-­risk infants, additional virologic diagnostic testing should be done at birth and 2-­6 wk after",2 6 additional after and at be birth definitions diagnostic done for high higher infants low of risk should testing virologic wk
728,1253,32.5,to <40 kg: 400 mg qd,40 400 kg mg qd to
729,1253,0.58,m2 to 0.83 m2: 200 mg,0 200 83 m2 mg to
730,1253,0.84,m2 to 1.16 m2: 300 mg,1 16 300 m2 mg to
731,1256,1.5,mg/kg/dose qd,dose kg mg qd
732,1258,7.5,mg/kg chloroquine phosphate),chloroquine kg mg phosphate
733,1263,7.4,yr,yr
734,1265,1.5,"mg/kg/day IV in 2 divided doses × 3 days, 1.5 mg/kg/day IV in 2 divided doses × 3 days,",1 2 3 5 day days divided doses in iv kg mg
735,1265,1.5,"mg/kg intrathecally daily × 2 days, then 1",1 2 daily days intrathecally kg mg then
736,1265,1.5,"mg/kg intrathecally daily × 2 days, then 1 mg/",1 2 daily days intrathecally kg mg then
737,1266,0.6,mg/kg/day IV in 4 divided doses × 4 days,4 day days divided doses in iv kg mg
738,1266,0.6,mg/kg/day IV in 4 divided doses × 4 days,4 day days divided doses in iv kg mg
739,1270,8.3,mg base/kg (10 mg salt/kg) PO tid × 3-­7,10 3 7 base kg mg po salt tid
740,1270,6.25,mg/kg PO qid × 7 days,7 days kg mg po qid
741,1270,0.5,mg/kg/day PO × 14 days,14 day days kg mg po
742,1270,8.3,mg base/kg (10 mg salt/kg) PO tid × 3-­7 days58,10 3 7 base days58 kg mg po salt tid
743,1270,6.25,mg/kg PO qid × 7 days,7 days kg mg po qid
744,1270,0.5,mg/kg/day PO × 14 days,14 day days kg mg po
745,1270,0.5,mg/kg/day PO × 14 days,14 day days kg mg po
746,1270,0.5,mg/kg/day PO × 14 days,14 day days kg mg po
747,1270,0.5,mg/kg/day PO × 14 days,14 day days kg mg po
748,1270,2.4,"mg/kg/dose IV × 3 days, at 0, 12, and 24 hr",0 12 24 3 and at days dose hr iv kg mg
749,1270,2.4,"mg/kg/dose IV × 3 days, at 0, 12, and 24 hr",0 12 24 3 and at days dose hr iv kg mg
750,1271,6.25,mg/kg PO qid × 7 days,7 days kg mg po qid
751,1271,0.6,mg base/kg/day PO × 14 days,14 base day days kg mg po
752,1271,0.5,mg/kg base (max 30 mg) daily beginning 1-­2,1 2 30 base beginning daily kg max mg
753,1272,0.3,mg/kg base PO (max 30 mg) daily × 21 days,21 30 base daily days kg max mg po
754,1272,0.3,mg/kg base PO daily (max 30 mg) × 21 days,21 30 base daily days kg max mg po
755,1273,1.5,g PO bid is a standard dose for a 100-­lb,100 a bid dose for g is lb po standard
756,1273,1.5,g PO bid is a standard dose for a 100-­lb,100 a bid dose for g is lb po standard
757,1277,328.1,Giardia duodenalis,duodenalis giardia
758,1278,328.2,Balantidiasis,balantidiasis
759,1279,7.5,mg/kg body weight [maximum 400 mg/dose] bid PO) is usually,400 bid body dose is kg maximum mg po usually weight
760,1291,0.5,mg base/kg PO qd × 14 days,14 base days kg mg po qd
761,1291,0.5,mg base/kg PO qd × 14 days,14 base days kg mg po qd
762,1292,334.3,for options and dosing),and dosing for options
763,1292,334.3,for options and dosing),and dosing for options
764,1293,0.5,mg/kg base (0.8 mg/kg salt),0 8 base kg mg salt
765,1293,0.5,mg/kg base (0.8 mg/kg salt),0 8 base kg mg salt
766,1302,4.1,"million disability-­adjusted life-­years, possibly leading all neglected",adjusted all disability leading life million neglected possibly years
767,1303,338.1,Cutaneous Larva Migrans,cutaneous larva migrans
768,1304,337.1,in Chapter 337).,337 chapter in
769,1310,348.1,summarizes the key features of tapeworms that affect children.,affect children features key of summarizes tapeworms that the
770,1310,0.5,× 1-­2 × 0.1 cm in size. Molecular methods can distinguish T. saginata from T. asiatica. Antigen detection tests are increasingly available.,0 1 2 antigen are asiatica available can cm detection distinguish from in increasingly methods molecular saginata size t tests
771,1315,352.1,and 352.4).,352 4 and
772,1315,0.5,L. Disorders that interfere with absorption in the small bowel tend,absorption bowel disorders in interfere l small tend that the with
773,1316,0.1,mg/kg/dose or 3 mg/m2/dose,3 dose kg m2 mg or
774,1317,12.5,mg increments,increments mg
775,1317,0.25,mg/kg/day PO in 1-­3 divided,1 3 day divided in kg mg po
776,1317,0.5,"to 1 mcg/kg subQ once daily,",1 daily kg mcg once subq to
777,1320,4.5,mo in utero,in mo utero
778,1320,5.5,mo in utero,in mo utero
779,1320,7.5,mo,mo
780,1320,6.5,mo,mo
781,1320,4.5,mo in utero,in mo utero
782,1320,4.5,mo in utero,in mo utero
783,1325,13.6,"mg fluoride, respectively. Fluoride varnish should be administered twice a year for preschool children at moderate caries risk and",a administered and at be caries children fluoride for mg moderate preschool respectively risk should twice varnish year
784,1330,364.1,Common Clinical Manifestations and,and clinical common manifestations
785,1330,365.1,Esophageal Atresia and,and atresia esophageal
786,1331,365.2,Laryngotracheoesophageal Clefts,clefts laryngotracheoesophageal
787,1331,365.3,Congenital Esophageal Stenosis,congenital esophageal stenosis
788,1335,369.1,Complications of Gastroesophageal,complications gastroesophageal of
789,1338,373.1,Foreign Bodies in the Esophagus,bodies esophagus foreign in the
790,1338,373.2,Caustic Ingestions,caustic ingestions
791,1340,375.1,Hypertrophic Pyloric Stenosis,hypertrophic pyloric stenosis
792,1341,375.2,Congenital Gastric Outlet Obstruction,congenital gastric obstruction outlet
793,1341,375.3,Gastric Duplication,duplication gastric
794,1342,375.4,Gastric Volvulus,gastric volvulus
795,1342,375.5,Hypertrophic Gastropathy,gastropathy hypertrophic
796,1342,376.1,Duodenal Obstruction,duodenal obstruction
797,1343,376.2,Jejunal and Ileal Atresia and,and atresia ileal jejunal
798,1343,376.3,Malrotation,malrotation
799,1344,377.1,Intestinal Duplication,duplication intestinal
800,1344,377.2,Meckel Diverticulum and Other,and diverticulum meckel other
801,1345,378.1,Chronic Intestinal Pseudoobstruction,chronic intestinal pseudoobstruction
802,1346,378.1,Chronic Intestinal Pseudoobstruction,chronic intestinal pseudoobstruction
803,1348,378.2,Mitochondrial Neurogastrointestinal,mitochondrial neurogastrointestinal
804,1348,378.3,Encopresis and Functional,and encopresis functional
805,1349,1.1,Absent neurons,absent neurons
806,1349,1.2,Decreased numbers of neurons,decreased neurons numbers of
807,1349,1.3,Increased numbers of neurons,increased neurons numbers of
808,1349,1.4,Degenerative neuropathy§,degenerative neuropathy
809,1349,1.5,Inflammatory neuropathies,inflammatory neuropathies
810,1349,1.6,Abnormal content in neurons,abnormal content in neurons
811,1349,1.7,Abnormal neurochemical coding**,abnormal coding neurochemical
812,1349,1.8,Relative immaturity of neurons,immaturity neurons of relative
813,1349,1.9,Abnormal enteric glia,abnormal enteric glia
814,1349,2.1,Muscularis propria malformations††,malformations muscularis propria
815,1349,2.2,Muscle cell degeneration,cell degeneration muscle
816,1349,2.3,Muscle hyperplasia/hypertrophy,hyperplasia hypertrophy muscle
817,1349,2.4,Abnormal content in myocytes,abnormal content in myocytes
818,1349,2.5,Abnormal supportive tissue,abnormal supportive tissue
819,1349,3.1,Abnormal ICC networks†††,abnormal icc networks
820,1349,1.5,g/kg body weight/day,body day g kg weight
821,1349,0.7,g/kg body weight/day,body day g kg weight
822,1350,378.4,Congenital Aganglionic Megacolon,aganglionic congenital megacolon
823,1351,378.7,Megacystis-­microcolon-­intestinal hypoperistalsis syndrome. Single frontal view of newborn female reveals the microcolon,female frontal hypoperistalsis intestinal megacystis microcolon newborn of reveals single syndrome the view
824,1351,378.5,Intestinal Neuronal Dysplasia,dysplasia intestinal neuronal
825,1352,378.6,Superior Mesenteric Artery Syndrome,artery mesenteric superior syndrome
826,1352,379.1,Ileus,ileus
827,1352,379.2,Adhesions,adhesions
828,1352,379.3,Intussusception,intussusception
829,1353,379.4,Closed-­Loop Obstructions,closed loop obstructions
830,1353,380.1,Foreign Bodies in the Stomach and,and bodies foreign in stomach the
831,1353,379.4,Closed-­Loop Obstructions,closed loop obstructions
832,1353,380.1,Foreign Bodies in the Stomach and,and bodies foreign in stomach the
833,1354,380.2,Bezoars,bezoars
834,1356,381.1,Zollinger-­Ellison Syndrome,ellison syndrome zollinger
835,1357,382.1,Chronic Ulcerative Colitis,chronic colitis ulcerative
836,1358,6.75,g/day). Sulfasalazine and the 5-­ASA preparations effectively treat,5 and asa day effectively g preparations sulfasalazine the treat
837,1359,382.2,"Crohn Disease (Regional Enteritis,",crohn disease enteritis regional
838,1363,382.3,Very Early Onset Inflammatory Bowel,bowel early inflammatory onset very
839,1367,385.1,Evaluation of Children with Suspected,children evaluation of suspected with
840,1370,385.2,Other Malabsorptive Syndromes,malabsorptive other syndromes
841,1372,385.4,and 385.5). Magnetic resonance lymphangiography may identify,385 5 and identify lymphangiography magnetic may resonance
842,1372,385.3,Intestinal Infections and Infestations,and infections infestations intestinal
843,1373,385.4,Immunodeficiency Disorders,disorders immunodeficiency
844,1374,385.6,Short Bowel Syndrome,bowel short syndrome
845,1374,385.7,Chronic Malnutrition,chronic malnutrition
846,1375,385.8,Enzyme Deficiencies,deficiencies enzyme
847,1375,0.5,"g/kg of glucose or galactose; if necessary, a second test can be performed using 2 g/kg. Breath hydrogen will rise more than 20 ppm. Biopsy",2 20 a be biopsy breath can g galactose glucose hydrogen if kg more necessary of or performed ppm rise second test than using will
848,1376,385.9,Liver and Biliary Disorders Causing,and biliary causing disorders liver
849,1377,385.10,Rare Inborn Defects Causing,causing defects inborn rare
850,1388,387.10,outline a clinical evaluation plan and management strategy for,a and clinical evaluation for management outline plan strategy
851,1390,387.1,Traveler’s Diarrhea,diarrhea s traveler
852,1394,388.1,Diarrhea from Neuroendocrine,diarrhea from neuroendocrine
853,1396,389.2,Biopsychosocial model,biopsychosocial model
854,1397,389.11,and 389.12). Management of symptoms may include dietary,12 389 and dietary include management may of symptoms
855,1404,392.1,Anorectal Malformations,anorectal malformations
856,1406,392.2,Anal Fissure,anal fissure
857,1406,392.3,Perianal Abscess and Fistula,abscess and fistula perianal
858,1407,392.4,Hemorrhoids,hemorrhoids
859,1407,392.5,Rectal Mucosal Prolapse,mucosal prolapse rectal
860,1414,395.1,Pancreatic Anatomic Abnormalities,abnormalities anatomic pancreatic
861,1415,395.2,Pancreatic Physiology,pancreatic physiology
862,1416,399.1,Acute Pancreatitis,acute pancreatitis
863,1418,399.2,Acute Recurrent and Chronic,acute and chronic recurrent
864,1422,1.5,to 5.5 cm (average: 3 cm) in infants to 4 to 8 cm in adolescents;,3 4 5 8 adolescents average cm in infants to
865,1424,403.1,Evaluation of Patients with Possible,evaluation of patients possible with
866,1425,404.1,Neonatal Cholestasis,cholestasis neonatal
867,1428,404.2,Cholestasis in the Older Child,child cholestasis in older the
868,1428,405.1,Inherited Deficient Conjugation of,conjugation deficient inherited of
869,1428,404.2,Cholestasis in the Older Child,child cholestasis in older the
870,1428,405.1,Inherited Deficient Conjugation of,conjugation deficient inherited of
871,1430,405.2,Wilson Disease,disease wilson
872,1431,405.3,Indian Childhood Cirrhosis,childhood cirrhosis indian
873,1431,405.4,Neonatal Hemochromatosis,hemochromatosis neonatal
874,1431,405.5,Miscellaneous Metabolic Diseases of,diseases metabolic miscellaneous of
875,1433,0.1,mL/kg,kg ml
876,1433,0.2,mL/kg,kg ml
877,1433,0.2,mL/kg (repeat every 2 mo),2 every kg ml mo repeat
878,1433,0.1,mL/kg,kg ml
879,1437,0.5,(1),1
880,1440,12.7,years.,years
881,1442,408.1,Nonalcoholic Fatty Liver Disease,disease fatty liver nonalcoholic
882,1443,1.73,m2,m2
883,1458,418.1,Chylous Ascites,ascites chylous
884,1459,419.1,Acute Primary Peritonitis,acute peritonitis primary
885,1459,419.2,Acute Secondary Peritonitis,acute peritonitis secondary
886,1459,419.3,Acute Secondary Localized Peritonitis,acute localized peritonitis secondary
887,1459,420.1,Incisional Hernia,hernia incisional
888,1467,422.1,Extrapulmonary Diseases with,diseases extrapulmonary with
889,1472,423.1,Sudden Unexpected Postnatal,postnatal sudden unexpected
890,1476,426.1,Nasal Foreign Bodies,bodies foreign nasal
891,1476,426.2,Epistaxis,epistaxis
892,1483,1.2,million units,million units
893,1485,432.1,and 432.2). Deep neck infections can be accurately identified and,2 432 accurately and be can deep identified infections neck
894,1485,432.1,and 432.2). Deep neck infections can be accurately identified and,2 432 accurately and be can deep identified infections neck
895,1487,433.1,Infectious Upper Airway Obstruction,airway infectious obstruction upper
896,1488,433.2,Bacterial Tracheitis,bacterial tracheitis
897,1489,434.1,Laryngomalacia,laryngomalacia
898,1489,434.2,Congenital Subglottic Stenosis,congenital stenosis subglottic
899,1489,434.3,Vocal Cord Paralysis,cord paralysis vocal
900,1490,434.4,Congenital Laryngeal Webs and,and congenital laryngeal webs
901,1490,434.5,Congenital Subglottic Hemangioma,congenital hemangioma subglottic
902,1490,434.7,Posterior Laryngeal Cleft and,and cleft laryngeal posterior
903,1490,434.6,Laryngoceles and Saccular Cysts,and cysts laryngoceles saccular
904,1491,434.8,Vascular and Cardiac Anomalies,and anomalies cardiac vascular
905,1491,434.9,"Tracheal Stenoses, Webs, and Atresia",and atresia stenoses tracheal webs
906,1491,434.10,Foregut Cysts,cysts foregut
907,1491,434.11,Tracheomalacia and Bronchomalacia,and bronchomalacia tracheomalacia
908,1492,435.1,Laryngeal Foreign Bodies,bodies foreign laryngeal
909,1492,435.2,Tracheal Foreign Bodies,bodies foreign tracheal
910,1492,435.3,Bronchial Foreign Bodies,bodies bronchial foreign
911,1492,436.1,Congenital Subglottic Stenosis,congenital stenosis subglottic
912,1493,436.2,Acquired Laryngotracheal Stenosis,acquired laryngotracheal stenosis
913,1494,436.2,Acquired Laryngotracheal Stenosis,acquired laryngotracheal stenosis
914,1495,438.1,Vocal Nodules,nodules vocal
915,1495,438.2,Recurrent Respiratory Papillomatosis,papillomatosis recurrent respiratory
916,1495,438.3,Congenital Subglottic Hemangioma,congenital hemangioma subglottic
917,1495,438.6,Tracheal Neoplasms,neoplasms tracheal
918,1495,438.7,Bronchial Tumors,bronchial tumors
919,1495,438.4,Vascular Malformations,malformations vascular
920,1495,438.5,Other Laryngeal Neoplasms,laryngeal neoplasms other
921,1496,439.1,Wheezing in Infants: Bronchiolitis,bronchiolitis in infants wheezing
922,1497,439.2,Bronchitis,bronchitis
923,1501,443.1,Bronchiolitis Obliterans,bronchiolitis obliterans
924,1501,443.2,Follicular Bronchitis,bronchitis follicular
925,1501,443.3,Pulmonary Alveolar Microlithiasis,alveolar microlithiasis pulmonary
926,1503,444.1,Pulmonary Agenesis and Aplasia,agenesis and aplasia pulmonary
927,1503,444.2,Pulmonary Hypoplasia,hypoplasia pulmonary
928,1503,444.3,Congenital Pulmonary Airway,airway congenital pulmonary
929,1504,444.4,Pulmonary Sequestration,pulmonary sequestration
930,1504,444.5,Bronchogenic Cysts,bronchogenic cysts
931,1504,444.6,Congenital Pulmonary,congenital pulmonary
932,1505,444.7,Lung Hernia,hernia lung
933,1505,444.8,Other Congenital Malformations of,congenital malformations of other
934,1508,447.1,"predispose the affected patients to aspiration, although technically they do not cause aspiration by themselves. These include but are",affected although are aspiration but by cause do include not patients predispose technically the themselves these they to
935,1509,448.1,Hypersensitivity Pneumonia,hypersensitivity pneumonia
936,1511,448.2,Occupational and Environmental Lung,and environmental lung occupational
937,1512,448.3,Granulomatous Lung Disease,disease granulomatous lung
938,1515,448.4,Eosinophilic Lung Disease,disease eosinophilic lung
939,1518,448.5,Interstitial Lung Disease,disease interstitial lung
940,1518,16.2,"cases/100,000 children. This large range in prevalence is likely a",000 100 a cases children in is large likely prevalence range this
941,1518,448.16,"and 448.17). Growth disorders such as alveolar simplification, unique diseases of infancy such as neuroendocrine cell hyperplasia of infancy (NEHI), and disorders of surfactant metabolism",17 448 alveolar and as cell diseases disorders growth hyperplasia infancy metabolism nehi neuroendocrine of simplification such surfactant unique
942,1521,448.6,Neuroendocrine Cell Hyperplasia of,cell hyperplasia neuroendocrine of
943,1522,448.7,Fibrotic Lung Disease,disease fibrotic lung
944,1526,0.25,μg/L) may help determine when to stop treatment.,determine help l may stop to treatment when μg
945,1526,449.1,COVID-­19,19 covid
946,1529,451.2,Serofibrinous or Serosanguineous,or serofibrinous serosanguineous
947,1529,451.1,Dry Pleurisy,dry pleurisy
948,1530,451.3,Empyema,empyema
949,1544,456.1,Inherited Disorders of Surfactant,disorders inherited of surfactant
950,1545,456.2,Pulmonary Alveolar Proteinosis,alveolar proteinosis pulmonary
951,1548,458.1,Pulmonary Embolus and Infarction,and embolus infarction pulmonary
952,1551,2.5,mg twice a day,a day mg twice
953,1551,458.2,Pulmonary Hemorrhage and,and hemorrhage pulmonary
954,1559,467.1,Pectus Excavatum (Funnel Chest),chest excavatum funnel pectus
955,1559,467.2,Pectus Carinatum and Sternal Clefts,and carinatum clefts pectus sternal
956,1559,467.3,Asphyxiating Thoracic Dystrophy,asphyxiating dystrophy thoracic
957,1559,467.4,Achondroplasia,achondroplasia
958,1560,467.5,Kyphoscoliosis: Adolescent Idiopathic,adolescent idiopathic kyphoscoliosis
959,1560,467.6,Congenital Rib Anomalies,anomalies congenital rib
960,1560,468.1,Chronic Respiratory Failure and Long-­,and chronic failure long respiratory
961,1561,468.2,Congenital Central Hypoventilation,central congenital hypoventilation
962,1564,468.3,Rapid-­Onset Obesity with Hypothalamic,hypothalamic obesity onset rapid with
963,1564,1.5,years of age; central hypoventilation beginning after age 1.5 years;,1 5 after age beginning central hypoventilation of years
964,1565,468.4,Long-­Term Ventilation and Technology,and long technology term ventilation
965,1567,469.1,Early Cardiac Morphogenesis,cardiac early morphogenesis
966,1567,469.2,Cardiac Looping,cardiac looping
967,1567,469.3,Cardiac Septation,cardiac septation
968,1568,469.4,Aortic Arch Development,aortic arch development
969,1568,469.5,Cardiac Differentiation,cardiac differentiation
970,1568,469.6,Developmental Changes in Cardiac,cardiac changes developmental in
971,1569,470.1,The Fetal Circulation,circulation fetal the
972,1569,470.2,The Transitional Circulation,circulation the transitional
973,1569,470.3,The Neonatal Circulation,circulation neonatal the
974,1569,470.4,Persistent Pulmonary Hypertension,hypertension persistent pulmonary
975,1574,472.1,Radiologic Cardiac Assessment,assessment cardiac radiologic
976,1575,472.2,Electrocardiography,electrocardiography
977,1578,472.3,Hematologic Data in Cardiovascular,cardiovascular data hematologic in
978,1578,472.4,Echocardiography,echocardiography
979,1580,472.5,Exercise Testing,exercise testing
980,1580,472.6,Cardiac Imaging Studies,cardiac imaging studies
981,1580,472.7,Diagnostic and Interventional Cardiac,and cardiac diagnostic interventional
982,1589,475.2,Ostium Secundum Defect,defect ostium secundum
983,1589,475.1,Atrial Septal Defect,atrial defect septal
984,1591,475.3,Sinus Venosus Atrial Septal Defect,atrial defect septal sinus venosus
985,1591,475.4,Partial Anomalous Pulmonary,anomalous partial pulmonary
986,1591,475.2,"and 475.3). When an ASD is detected by echocardiography, one",3 475 an and asd by detected echocardiography is one when
987,1591,475.5,Atrioventricular Septal Defects,atrioventricular defects septal
988,1592,475.6,Ventricular Septal Defect,defect septal ventricular
989,1593,475.7,Supracristal Ventricular Septal Defect,defect septal supracristal ventricular
990,1593,475.8,Patent Ductus Arteriosus,arteriosus ductus patent
991,1594,475.9,Aortopulmonary Window Defect,aortopulmonary defect window
992,1595,475.10,Coronary Artery Fistula,artery coronary fistula
993,1595,475.11,Ruptured Sinus of Valsalva Aneurysm,aneurysm of ruptured sinus valsalva
994,1595,476.1,Pulmonary Valve Stenosis with Intact,intact pulmonary stenosis valve with
995,1596,476.2,Infundibular Pulmonary Stenosis and,and infundibular pulmonary stenosis
996,1596,476.3,Pulmonary Stenosis in Combination,combination in pulmonary stenosis
997,1596,476.4,Peripheral Pulmonary Stenosis,peripheral pulmonary stenosis
998,1596,476.5,Aortic Stenosis,aortic stenosis
999,1598,476.6,Coarctation of the Aorta,aorta coarctation of the
1000,1599,476.7,Coarctation with Ventricular Septal,coarctation septal ventricular with
1001,1599,476.8,Coarctation with Other Cardiac,cardiac coarctation other with
1002,1599,476.9,Congenital Mitral Stenosis,congenital mitral stenosis
1003,1599,476.10,Pulmonary Venous Hypertension,hypertension pulmonary venous
1004,1600,477.1,Pulmonary Valvular Insufficiency and,and insufficiency pulmonary valvular
1005,1600,477.2,Congenital Mitral Insufficiency,congenital insufficiency mitral
1006,1600,477.3,Mitral Valve Prolapse,mitral prolapse valve
1007,1600,477.4,Tricuspid Regurgitation,regurgitation tricuspid
1008,1600,477.3,Mitral Valve Prolapse,mitral prolapse valve
1009,1600,477.4,Tricuspid Regurgitation,regurgitation tricuspid
1010,1601,479.1,Tetralogy of Fallot,fallot of tetralogy
1011,1603,479.2,Tetralogy of Fallot with Pulmonary,fallot of pulmonary tetralogy with
1012,1604,479.3,Pulmonary Atresia with Intact,atresia intact pulmonary with
1013,1604,479.4,Tricuspid Atresia,atresia tricuspid
1014,1605,479.5,Double-­Outlet Right Ventricle,double outlet right ventricle
1015,1606,479.6,Transposition of the Great Arteries,arteries great of the transposition
1016,1606,479.7,Ebstein Anomaly of the Tricuspid,anomaly ebstein of the tricuspid
1017,1607,480.2,d-­Transposition of the Great Arteries,arteries d great of the transposition
1018,1607,480.1,d-­Transposition of the Great Arteries,arteries d great of the transposition
1019,1608,480.3,Transposition of the Great Arteries,arteries great of the transposition
1020,1608,480.4,l-­Transposition of the Great Arteries,arteries great l of the transposition
1021,1609,480.5,Double-­Outlet Right Ventricle,double outlet right ventricle
1022,1609,480.6,Double-­Outlet Right Ventricle with,double outlet right ventricle with
1023,1609,480.7,Total Anomalous Pulmonary Venous,anomalous pulmonary total venous
1024,1610,480.8,Truncus Arteriosus,arteriosus truncus
1025,1610,480.9,Single Ventricle (Double-­Inlet,double inlet single ventricle
1026,1611,480.10,Hypoplastic Left Heart Syndrome,heart hypoplastic left syndrome
1027,1612,480.11,Abnormal Positions of the Heart,abnormal heart of positions the
1028,1614,481.1,Anomalies of the Aortic Arch,anomalies aortic arch of the
1029,1615,481.2,Anomalous Origin of the Coronary,anomalous coronary of origin the
1030,1616,481.3,Pulmonary Arteriovenous Fistula,arteriovenous fistula pulmonary
1031,1616,481.4,Ectopia Cordis,cordis ectopia
1032,1616,481.5,Diverticulum of the Left Ventricle,diverticulum left of the ventricle
1033,1617,482.1,Primary Pulmonary Hypertension,hypertension primary pulmonary
1034,1617,482.1,and 482.2). PH is often characterized by progressive vascular,2 482 and by characterized is often ph progressive vascular
1035,1617,1.1,Idiopathic PAH,idiopathic pah
1036,1617,1.2,Heritable PAH,heritable pah
1037,1617,1.3,Drug-­ and toxin-­induced PAH,and drug induced pah toxin
1038,1617,1.4,PAH associated with:,associated pah with
1039,1617,1.5,PAH long-­term responders to calcium channel blockers,blockers calcium channel long pah responders term to
1040,1617,1.6,PAH with overt features of venous/capillaries (PVOD/PCH),capillaries features of overt pah pch pvod venous with
1041,1617,1.7,Persistent PH of the newborn syndrome,newborn of persistent ph syndrome the
1042,1617,2.1,PH due to heart failure with preserved LVEF,due failure heart lvef ph preserved to with
1043,1617,2.2,PH due to heart failure with reduced LVEF,due failure heart lvef ph reduced to with
1044,1617,2.3,Valvular heart disease,disease heart valvular
1045,1617,2.4,Congenital/acquired cardiovascular conditions leading to,acquired cardiovascular conditions congenital leading to
1046,1617,3.1,Obstructive lung disease,disease lung obstructive
1047,1617,3.2,Restrictive lung disease,disease lung restrictive
1048,1617,3.3,Other lung disease with mixed restrictive/obstructive pattern,disease lung mixed obstructive other pattern restrictive with
1049,1617,3.4,Hypoxia without lung disease,disease hypoxia lung without
1050,1617,3.5,Developmental lung disorders,developmental disorders lung
1051,1617,4.1,Chronic thromboembolic pulmonary hypertension,chronic hypertension pulmonary thromboembolic
1052,1617,4.2,Other pulmonary artery obstructions,artery obstructions other pulmonary
1053,1617,5.1,Hematologic disorders,disorders hematologic
1054,1617,5.2,Systemic and metabolic disorders,and disorders metabolic systemic
1055,1617,5.3,Others,others
1056,1617,5.4,Complex congenital heart disease.,complex congenital disease heart
1057,1617,482.2,Pulmonary Vascular Disease,disease pulmonary vascular
1058,1620,483.1,Congenital Heart Disease in Adults,adults congenital disease heart in
1059,1623,484.1,Principles of Antiarrhythmic Therapy,antiarrhythmic of principles therapy
1060,1623,484.2,Sinus Arrhythmias and Extrasystoles,and arrhythmias extrasystoles sinus
1061,1625,484.3,Supraventricular Tachycardia,supraventricular tachycardia
1062,1628,484.4,Ventricular Tachyarrhythmias,tachyarrhythmias ventricular
1063,1628,484.5,Long QT Syndromes,long qt syndromes
1064,1629,484.6,Sinus Node Dysfunction,dysfunction node sinus
1065,1630,2.52,sec,sec
1066,1630,2.0,sec,sec
1067,1630,484.7,Atrioventricular Block,atrioventricular block
1068,1639,488.1,Dilated Cardiomyopathy,cardiomyopathy dilated
1069,1639,488.4,"and 488.5). Disorders of fatty acid oxidation present with systemic derangements of metabolism (hypoketotic hypoglycemia, acidosis, and hepatic dysfunction), some with peripheral myopathy and",488 5 acid acidosis and derangements disorders dysfunction fatty hepatic hypoglycemia hypoketotic metabolism myopathy of oxidation peripheral present some systemic with
1070,1643,488.2,Hypertrophic Cardiomyopathy,cardiomyopathy hypertrophic
1071,1644,488.3,Restrictive Cardiomyopathy,cardiomyopathy restrictive
1072,1645,488.4,"Left Ventricular Noncompaction,",left noncompaction ventricular
1073,1645,488.5,Myocarditis,myocarditis
1074,1647,489.1,Acute Pericarditis,acute pericarditis
1075,1648,489.2,Constrictive Pericarditis,constrictive pericarditis
1076,1650,491.5,lists other causes of an elevated BNP.,an bnp causes elevated lists of other
1077,1652,491.4,and the dosing in Table 491.7.,491 7 and dosing in table the
1078,1653,491.1,Cardiogenic Shock,cardiogenic shock
1079,1653,492.1,Pediatric Heart Transplantation,heart pediatric transplantation
1080,1653,492.1,Pediatric Heart Transplantation,heart pediatric transplantation
1081,1655,492.2,Heart-­Lung and Lung Transplantation,and heart lung transplantation
1082,1655,493.1,Aneurysms,aneurysms
1083,1655,493.2,Arteriovenous Fistulas,arteriovenous fistulas
1084,1656,493.4,Arterial Tortuosity,arterial tortuosity
1085,1656,493.3,Generalized Arterial Calcification of,arterial calcification generalized of
1086,1661,3.3,mg/kg/day up to 100 mg/day,100 day kg mg to up
1087,1661,0.2,mg/kg/day up to,day kg mg to up
1088,1661,0.5,mg/kg/dose (0.05 mg/,0 05 dose kg mg
1089,1661,0.08,mg/kg/day,day kg mg
1090,1661,0.1,mg/kg/day up to,day kg mg to up
1091,1661,0.07,mg/kg/day up to,day kg mg to up
1092,1661,1.6,mg/m2/day,day m2 mg
1093,1661,0.6,mg/kg/day up to 40 mg/day,40 day kg mg to up
1094,1661,0.6,mg/kg/day up to 40 mg/day,40 day kg mg to up
1095,1661,0.6,mg/kg/day up to 40 mg/day,40 day kg mg to up
1096,1661,0.6,mg/kg/day up to 40 mg/day,40 day kg mg to up
1097,1661,0.75,mg/kg/day up to,day kg mg to up
1098,1661,1.4,mg/kg/day up to 100 mg/day,100 day kg mg to up
1099,1661,0.1,mg/kg/dose up to,dose kg mg to up
1100,1661,6.25,mg bid,bid mg
1101,1661,0.5,mg/kg/dose up to 25 mg bid,25 bid dose kg mg to up
1102,1661,2.5,mg/day,day mg
1103,1661,0.6,mg/kg/day up to 10 mg/day,10 day kg mg to up
1104,1661,0.3,mg/kg/day,day kg mg
1105,1661,0.25,mg/kg/dose,dose kg mg
1106,1661,7.5,mg/kg/day up to 200 mg/day,200 day kg mg to up
1107,1662,0.25,"mg/kg/dose, up to 25 mg/",25 dose kg mg to up
1108,1670,500.1,Anemia of Chronic Disease,anemia chronic disease of
1109,1671,500.1,Anemia of Chronic Disease,anemia chronic disease of
1110,1671,500.2,Anemia of Renal Disease,anemia disease of renal
1111,1673,58.7,%,
1112,1673,17.3,%,
1113,1673,14.8,%,
1114,1673,3.3,%,
1115,1673,2.2,%,
1116,1673,0.4,%,
1117,1673,0.4,%,
1118,1673,1.4,%,
1119,1673,1.8,%,
1120,1673,3.4,%,
1121,1673,12.1,%,
1122,1673,1.4,%,
1123,1673,77.9,%,
1124,1673,4.0,%,
1125,1673,1.1,%,
1126,1675,503.1,Folic Acid Deficiency,acid deficiency folic
1127,1676,503.2,Vitamin B12 (Cobalamin) Deficiency,b12 cobalamin deficiency vitamin
1128,1677,503.3,Other Rare Megaloblastic Anemias,anemias megaloblastic other rare
1129,1677,503.3,Other Rare Megaloblastic Anemias,anemias megaloblastic other rare
1130,1683,4.1,"complex, leading to membrane instability (see Fig. 507.1). The usual",1 507 complex fig instability leading membrane see the to usual
1131,1684,4.1,"complex, leading to membrane instability (see Fig. 507.1). The usual",1 507 complex fig instability leading membrane see the to usual
1132,1686,511.1,Sickle Cell Disease,cell disease sickle
1133,1692,511.2,Sickle Cell Trait (Hemoglobin AS),as cell hemoglobin sickle trait
1134,1692,511.3,Other Hemoglobinopathies,hemoglobinopathies other
1135,1692,511.4,Unstable Hemoglobin Disorders,disorders hemoglobin unstable
1136,1693,511.5,Abnormal Hemoglobins with,abnormal hemoglobins with
1137,1693,511.7,Hereditary Methemoglobinemia,hereditary methemoglobinemia
1138,1693,511.6,Abnormal Hemoglobins Causing,abnormal causing hemoglobins
1139,1693,511.8,Hereditary Methemoglobinemia with,hereditary methemoglobinemia with
1140,1693,11.7,g/dL × 0.01 = 0.117 g/dL (left) and 11.7 g/dL × 0.72 = 8.42 g/dL,0 01 11 117 42 7 72 8 and dl g left
1141,1693,0.1,"mL of a 0.144 molar solution of sodium nitrate (right), and 0.1 mL of",0 1 144 a and ml molar nitrate of right sodium solution
1142,1693,511.9,Syndromes of Hereditary Persistence,hereditary of persistence syndromes
1143,1694,511.10,Thalassemia Syndromes,syndromes thalassemia
1144,1695,10.5,"g/dL. Ongoing monitoring for transfusion-­associated transmitted infections (hepatitis A, B, and C, HIV), alloimmunization, annual",a alloimmunization and annual associated b c dl for g hepatitis hiv infections monitoring ongoing transfusion transmitted
1145,1697,512.1,Pyruvate Kinase Deficiency,deficiency kinase pyruvate
1146,1698,512.2,Other Glycolytic Enzyme Deficiencies,deficiencies enzyme glycolytic other
1147,1698,512.3,Glucose-­6-­Phosphate Dehydrogenase,6 dehydrogenase glucose phosphate
1148,1713,523.1,and Fig. 523.1). Taking nucleic acid amplification testing (NAT),1 523 acid amplification and fig nat nucleic taking testing
1149,1715,524.1,Clinical and Laboratory Evaluation of,and clinical evaluation laboratory of
1150,1717,524.1,provides an approach to the differential diagnosis of many common bleeding disorders based on screening tests.,an approach based bleeding common diagnosis differential disorders many of on provides screening tests the to
1151,1717,11.2,(9.5-­12.6),12 5 6 9
1152,1717,11.0,(9.7-­12.8),12 7 8 9
1153,1717,11.0,(9.8-­13.0),0 13 8 9
1154,1717,11.3,(9.9-­13.4),13 4 9
1155,1717,11.7,(10.0-­14.6),0 10 14 6
1156,1717,11.8,(10.0-­14.1),0 1 10 14
1157,1717,10.9,(9.2-­12.2),12 2 9
1158,1717,35.4,(27.6-­45.6),27 45 6
1159,1717,33.5,(24.8-­40.7),24 40 7 8
1160,1717,32.4,(25.1-­40.7),1 25 40 7
1161,1717,31.6,(24.0-­39.2),0 2 24 39
1162,1717,31.6,(26.9-­38.7),26 38 7 9
1163,1717,31.0,(24.6-­38.4),24 38 4 6
1164,1717,31.7,(27.8-­36.3),27 3 36 8
1165,1717,2.54,(1.43-­4.02),02 1 4 43
1166,1717,2.26,(1.50-­3.76),1 3 50 76
1167,1717,2.33,(1.57-­3.60),1 3 57 60
1168,1717,2.73,(1.88-­4.13),1 13 4 88
1169,1717,2.78,(1.89-­4.75),1 4 75 89
1170,1717,2.66,(1.77-­4.20),1 20 4 77
1171,1717,2.75,(2.17-­3.42),17 2 3 42
1172,1718,525.1,Factor VIII or Factor IX Deficiency,deficiency factor ix or viii
1173,1718,524.1,in Chapter 524 for a depiction of the in vitro clotting process as it,524 a as chapter clotting depiction for in it of process the vitro
1174,1720,525.2,Factor XI Deficiency,deficiency factor xi
1175,1720,525.3,Deficiencies of the Contact Factors,contact deficiencies factors of the
1176,1720,525.4,Factor VII Deficiency,deficiency factor vii
1177,1720,525.5,Factor X Deficiency,deficiency factor x
1178,1720,525.6,Prothrombin (Factor II) Deficiency,deficiency factor ii prothrombin
1179,1720,525.7,Factor V Deficiency,deficiency factor v
1180,1720,525.8,Combined Deficiency of Factors V,combined deficiency factors of v
1181,1720,525.9,Congenital Fibrinogen Disorders,congenital disorders fibrinogen
1182,1720,525.10,Factor XIII Deficiency (Fibrin-­Stabilizing,deficiency factor fibrin stabilizing xiii
1183,1720,525.11,Antiplasmin or Plasminogen,antiplasmin or plasminogen
1184,1722,0.3,μg/kg IV†,iv kg μg
1185,1724,528.1,Anticoagulant and Thrombolytic,and anticoagulant thrombolytic
1186,1724,528.4,and 528.5). Clinical trials of several direct oral anticoagulants,5 528 and anticoagulants clinical direct of oral several trials
1187,1728,533.1,Immune Thrombocytopenia,immune thrombocytopenia
1188,1731,533.2,Drug-­Induced Thrombocytopenia,drug induced thrombocytopenia
1189,1731,533.3,Nonimmune Platelet Destruction,destruction nonimmune platelet
1190,1731,533.4,Hemolytic-­Uremic Syndrome,hemolytic syndrome uremic
1191,1731,533.5,Thrombotic Thrombocytopenic,thrombocytopenic thrombotic
1192,1731,533.6,Kasabach-­Merritt Syndrome,kasabach merritt syndrome
1193,1731,533.7,Sequestration,sequestration
1194,1731,533.8,Congenital Thrombocytopenic,congenital thrombocytopenic
1195,1732,533.9,Neonatal Thrombocytopenia,neonatal thrombocytopenia
1196,1732,533.10,Thrombocytopenia From Acquired,acquired from thrombocytopenia
1197,1732,533.11,Platelet Function Disorders,disorders function platelet
1198,1732,533.12,Acquired Disorders of Platelet,acquired disorders of platelet
1199,1733,533.13,Congenital Abnormalities of Platelet,abnormalities congenital of platelet
1200,1733,533.14,Disorders of the Blood Vessels,blood disorders of the vessels
1201,1733,533.14,Disorders of the Blood Vessels,blood disorders of the vessels
1202,1741,539.1,Kikuchi-­Fujimoto Disease (Histiocytic,disease fujimoto histiocytic kikuchi
1203,1741,539.2,Sinus Histiocytosis with Massive,histiocytosis massive sinus with
1204,1742,539.3,Castleman Disease (Angiofollicular,angiofollicular castleman disease
1205,1742,4.5,(37/4),37 4
1206,1742,0.8,(—),
1207,1742,0.4,(0.7),0 7
1208,1753,544.1,Acute Lymphoblastic Leukemia,acute leukemia lymphoblastic
1209,1755,2.2,(CI:1.6–3.0),0 1 3 6 ci
1210,1755,0.1,197,197
1211,1755,1.9,(CI:1.3–2.7),1 2 3 7 ci
1212,1755,0.1,197,197
1213,1755,544.2,Acute Myelogenous Leukemia,acute leukemia myelogenous
1214,1756,544.3,Down Syndrome and Acute,acute and down syndrome
1215,1756,544.4,Chronic Myelogenous Leukemia,chronic leukemia myelogenous
1216,1757,544.5,Juvenile Myelomonocytic Leukemia,juvenile leukemia myelomonocytic
1217,1757,544.6,Infant Leukemia,infant leukemia
1218,1757,545.1,Hodgkin Lymphoma,hodgkin lymphoma
1219,1759,545.2,Non-­Hodgkin Lymphoma,hodgkin lymphoma non
1220,1761,545.8,and 545.9). Surgery is used mainly for diagnosis. Radiation,545 9 and diagnosis for is mainly radiation surgery used
1221,1762,545.3,Late Effects in Children and,and children effects in late
1222,1762,545.3,Late Effects in Children and,and children effects in late
1223,1765,546.7,"A, Sagittal T1-­",a sagittal t1
1224,1765,546.9,"A, Sagittal T1-­",a sagittal t1
1225,1770,548.1,Wilms Tumor,tumor wilms
1226,1770,548.1,Wilms Tumor,tumor wilms
1227,1773,548.2,Other Pediatric Renal Tumors,other pediatric renal tumors
1228,1776,550.1,Malignant Tumors of Bone,bone malignant of tumors
1229,1777,550.2,Benign Tumors and Tumor-­Like,and benign like tumor tumors
1230,1779,2.1,mean). Open biopsy and bone grafting with or without internal,and biopsy bone grafting internal mean open or with without
1231,1787,555.1,Thyroid Tumors,thyroid tumors
1232,1788,555.2,Nasopharyngeal Carcinoma,carcinoma nasopharyngeal
1233,1788,555.3,Adenocarcinoma of the Colon and,adenocarcinoma and colon of the
1234,1788,555.4,Adrenal Tumors,adrenal tumors
1235,1788,555.5,Desmoplastic Small Round Cell Tumor,cell desmoplastic round small tumor
1236,1789,556.1,Langerhans Cell Histiocytosis,cell histiocytosis langerhans
1237,1792,556.2,Hemophagocytic Lymphohistiocytosis,hemophagocytic lymphohistiocytosis
1238,1794,556.3,Other Histiocytoses,histiocytoses other
1239,1794,557.1,Anatomy of the Glomerulus,anatomy glomerulus of the
1240,1795,557.2,Glomerular Filtration,filtration glomerular
1241,1795,557.3,Glomerular Diseases,diseases glomerular
1242,1798,559.1,Immunoglobulin A Nephropathy,a immunoglobulin nephropathy
1243,1798,559.2,Alport Syndrome,alport syndrome
1244,1799,559.3,Thin Basement Membrane Disease,basement disease membrane thin
1245,1799,559.4,Acute Poststreptococcal,acute poststreptococcal
1246,1800,559.5,Membranous Nephropathy,membranous nephropathy
1247,1801,559.6,Membranoproliferative,membranoproliferative
1248,1801,559.7,Rapidly Progressive (Crescentic),crescentic progressive rapidly
1249,1802,560.1,Chronic Infections,chronic infections
1250,1802,560.2,Glomerulonephritis Associated with,associated glomerulonephritis with
1251,1803,560.3,IgA Vasculitis Nephritis,iga nephritis vasculitis
1252,1804,560.4,Goodpasture Disease,disease goodpasture
1253,1804,560.5,Hemolytic-­Uremic Syndrome,hemolytic syndrome uremic
1254,1806,560.6,Toxic Nephropathy,nephropathy toxic
1255,1806,560.7,Cortical Necrosis,cortical necrosis
1256,1806,560.8,Coagulopathies and,and coagulopathies
1257,1807,561.1,Pyelonephritis,pyelonephritis
1258,1807,561.2,Tubulointerstitial Nephritis,nephritis tubulointerstitial
1259,1809,561.3,Papillary Necrosis,necrosis papillary
1260,1809,561.4,Acute Tubular Necrosis,acute necrosis tubular
1261,1810,562.1,Vascular Abnormalities,abnormalities vascular
1262,1810,562.2,Renal Vein Thrombosis,renal thrombosis vein
1263,1810,562.3,Sickle Cell Nephropathy,cell nephropathy sickle
1264,1810,562.4,Idiopathic Hypercalciuria,hypercalciuria idiopathic
1265,1810,562.5,Nephrocalcinosis,nephrocalcinosis
1266,1811,563.1,Congenital Anomalies,anomalies congenital
1267,1811,563.2,Autosomal Recessive Polycystic,autosomal polycystic recessive
1268,1811,563.1,and 563.2).,2 563 and
1269,1811,563.3,Autosomal Dominant Polycystic,autosomal dominant polycystic
1270,1813,563.4,Trauma,trauma
1271,1813,563.5,Renal Tumors,renal tumors
1272,1813,564.1,Infectious Causes of Cystitis and,and causes cystitis i nfectious of
1273,1813,564.2,Hemorrhagic Cystitis,cystitis hemorrhagic
1274,1813,564.3,Vigorous Exercise,exercise vigorous
1275,1814,566.1,Transient Proteinuria,proteinuria transient
1276,1814,566.2,Orthostatic (Postural) Proteinuria,orthostatic postural proteinuria
1277,1814,566.3,Fixed Proteinuria,fixed proteinuria
1278,1815,0.3,g/1.73 m2/day,1 73 day g m2
1279,1817,567.1,Idiopathic Nephrotic Syndrome,idiopathic nephrotic syndrome
1280,1820,567.2,Secondary Nephrotic Syndrome,nephrotic secondary syndrome
1281,1820,567.3,Congenital Nephrotic Syndrome,congenital nephrotic syndrome
1282,1821,569.1,Proximal (Type II) Renal Tubular,ii proximal renal tubular type
1283,1822,569.2,Distal (Type I) Renal Tubular Acidosis,acidosis distal i renal tubular type
1284,1822,569.3,Hyperkalemic (Type IV) Renal Tubular,hyperkalemic iv renal tubular type
1285,1823,569.4,Rickets Associated with Renal Tubular,associated renal rickets tubular with
1286,1824,571.1,Bartter Syndrome,bartter syndrome
1287,1825,571.2,Gitelman Syndrome,gitelman syndrome
1288,1825,571.3,Other Inherited Tubular Transport,inherited other transport tubular
1289,1825,572.1,Acute Kidney Injury,acute injury kidney
1290,1825,3.0,"times baseline, OR",baseline or times
1291,1828,572.2,Chronic Kidney Disease,chronic disease kidney
1292,1830,572.3,End-­Stage Kidney Disease,disease end kidney stage
1293,1836,575.5,and 575.6).,575 6 and
1294,1837,99.8,(99–100),100 99
1295,1854,1.1,± 0.2 cm. The diagnosis of micropenis in a male newborn is if the,0 2 a cm diagnosis if in is male micropenis newborn of the
1296,1861,3.3,mg/dL GFR†,dl gfr mg
1297,1861,1.73,m2/24 hr,24 hr m2
1298,1862,0.4,"mg at bedtime, may facilitate stone passage by decreasing ureteral",at bedtime by decreasing facilitate may mg passage stone ureteral
1299,1873,7.5,g/m2 in women and females <20,20 and females g in m2 women
1300,1881,0.35,"mg) can cause significant irregular spotting, so if full suppression is the goal, then other progestins can be used daily, such as",as be can cause daily full goal if irregular is mg other progestins significant so spotting such suppression the then used
1301,1882,593.2,lists potential risks and protective factors for FGM.,and factors fgm for lists potential protective risks
1302,1892,0.5,mg/day until cessation of growth occurs. Short-­term side effects,cessation day effects growth mg occurs of short side term until
1303,1893,598.1,Overgrowth Syndromes,overgrowth syndromes
1304,1896,600.1,Central Precocious Puberty,central precocious puberty
1305,1897,600.1,"and 600.2). For females, these include tumors of the ovaries, autonomously functioning ovarian cysts, feminizing adrenal",2 600 adrenal and autonomously cysts females feminizing for functioning include of ovarian ovaries the these tumors
1306,1898,600.2,Precocious Puberty Resulting from,from precocious puberty resulting
1307,1899,600.3,Precocious Puberty After Irradiation,after irradiation precocious puberty
1308,1899,600.4,Syndrome of Precocious Puberty and,and of precocious puberty syndrome
1309,1899,600.5,Chorionic Gonadotropin-­Secreting,chorionic gonadotropin secreting
1310,1899,600.6,McCune-­Albright Syndrome,albright mccune syndrome
1311,1900,600.7,Familial Male-­Limited Gonadotropin-­,familial gonadotropin limited male
1312,1900,2.5,"mg/day or anastrozole 1 mg/day) has been used—the latter compounds to suppress estrogens derived from androgens, which potently",1 anastrozole androgens been compounds day derived estrogens from has latter mg or potently suppress the to used which
1313,1900,600.8,Incomplete (Partial) Precocious,incomplete partial precocious
1314,1900,600.9,Medicational Precocity,medicational precocity
1315,1900,600.10,Delayed or Absent Puberty,absent delayed or puberty
1316,1904,601.1,Thyroid Hormone Studies,hormone studies thyroid
1317,1910,605.1,Congenital Goiter,congenital goiter
1318,1910,605.2,Intratracheal Goiter,goiter intratracheal
1319,1910,605.3,Endemic Goiter and Cretinism,and cretinism endemic goiter
1320,1911,605.4,Acquired Goiter,acquired goiter
1321,1911,606.1,Graves Disease,disease graves
1322,1914,606.2,Congenital Hyperthyroidism,congenital hyperthyroidism
1323,1915,607.1,Thyroid Nodules,nodules thyroid
1324,1918,611.1,and Fig. 611.1). After the second to third day and during the first,1 611 after and day during fig first second the third to
1325,1922,613.1,Other Causes of Hypercalcemia,causes hypercalcemia of other
1326,1923,614.1,Histology and Embryology,and embryology histology
1327,1923,614.2,Adrenal Steroid Biosynthesis,adrenal biosynthesis steroid
1328,1924,614.1,and 614.2). Shortly after the fetal adrenal gland forms (weeks,2 614 adrenal after and fetal forms gland shortly the weeks
1329,1924,614.3,Regulation of the Adrenal Cortex,adrenal cortex of regulation the
1330,1925,614.4,Adrenal Steroid Hormone Actions,actions adrenal hormone steroid
1331,1926,614.5,Adrenal Medulla,adrenal medulla
1332,1926,615.1,Primary Adrenal Insufficiency,adrenal insufficiency primary
1333,1926,106.2,and 639.3). High levels of very long-­chain fatty acids are found,3 639 acids and are chain fatty found high levels long of very
1334,1930,615.2,Secondary and Tertiary Adrenal,adrenal and secondary tertiary
1335,1931,615.3,Adrenal Insufficiency in the Critical,adrenal critical in insufficiency the
1336,1931,615.4,Altered End-­Organ Sensitivity to,altered end organ sensitivity to
1337,1932,616.1,Congenital Adrenal Hyperplasia,adrenal congenital hyperplasia
1338,1935,0.4,"mg daily, and often require sodium supplementation (sodium chloride 8 mmol/kg) in addition to the mineralocorticoid. Older infants",8 addition and chloride daily in infants kg mg mineralocorticoid mmol often older require sodium supplementation the to
1339,1935,616.3,Congenital Adrenal Hyperplasia,adrenal congenital hyperplasia
1340,1935,616.2,Congenital Adrenal Hyperplasia,adrenal congenital hyperplasia
1341,1936,616.4,Congenital Adrenal Hyperplasia,adrenal congenital hyperplasia
1342,1936,616.5,Lipoid Adrenal Hyperplasia,adrenal hyperplasia lipoid
1343,1936,616.6,Deficiency of P450 Oxidoreductase,deficiency of oxidoreductase p450
1344,1936,616.7,Aldosterone Synthase Deficiency,aldosterone deficiency synthase
1345,1937,616.8,Glucocorticoid-­Remediable,glucocorticoid remediable
1346,1937,617.1,Adrenocortical Carcinoma,adrenocortical carcinoma
1347,1938,617.2,Adrenal Incidentaloma,adrenal incidentaloma
1348,1938,617.3,Adrenal Calcification,adrenal calcification
1349,1944,13.5,"years of age, reaching maturity at 13-­17 years of age. In a minority",13 17 a age at in maturity minority of reaching years
1350,1945,623.1,Hypergonadotropic Hypogonadism in,hypergonadotropic hypogonadism in
1351,1947,623.2,Hypogonadotropic Hypogonadism in,hypogonadism hypogonadotropic in
1352,1949,626.1,Hypergonadotropic Hypogonadism in,hypergonadotropic hypogonadism in
1353,1952,626.2,Hypogonadotropic Hypogonadism,hypogonadism hypogonadotropic
1354,1953,628.1,illustrates the production of steroid hormones in various glands and,and glands hormones illustrates in of production steroid the various
1355,1954,628.1,"46,XX DSD",46 dsd xx
1356,1956,628.2,"46,XY DSD",46 dsd xy
1357,1958,628.3,Ovotesticular DSD,dsd ovotesticular
1358,1959,629.1,Classification of Diabetes Mellitus,classification diabetes mellitus of
1359,1960,7.0,mmol/L),l mmol
1360,1960,629.2,Type 1 Diabetes Mellitus (Immune,1 diabetes immune mellitus type
1361,1960,32.9,in Whites.,in whites
1362,1961,13.1,- 14.4,14 4
1363,1964,1.6,mEq,meq
1364,1965,0.2,units/kg/day,day kg units
1365,1970,629.3,Type 2 Diabetes Mellitus,2 diabetes mellitus type
1366,1972,629.4,Other Specific Types of Diabetes,diabetes of other specific types
1367,1982,631.1,Neural Tube Defects,defects neural tube
1368,1982,631.2,Myelomeningocele,myelomeningocele
1369,1983,631.3,Occult Spinal Dysraphism,dysraphism occult spinal
1370,1983,631.3,and 631.4). A spine x-­ray in simple spina bifida occulta shows a,4 631 a and bifida in occulta ray shows simple spina spine x
1371,1983,631.4,Encephalocele,encephalocele
1372,1984,631.5,Anencephaly,anencephaly
1373,1984,631.6,Malformations of Cortical,cortical malformations of
1374,1986,631.7,Disorders with Midline Defects,defects disorders midline with
1375,1989,631.8,Dysgenesis of the Cranial Nerves and,and cranial dysgenesis nerves of the
1376,1990,631.9,Hydrocephalus,hydrocephalus
1377,1992,631.10,Craniosynostosis,craniosynostosis
1378,1999,633.1,Febrile Seizures,febrile seizures
1379,2000,633.2,Unprovoked Seizures,seizures unprovoked
1380,2001,633.3,Focal Seizures and Related Epilepsy,and epilepsy focal related seizures
1381,2001,633.4,Generalized Seizures and Related,and generalized related seizures
1382,2003,633.5,Mechanisms of Seizures,mechanisms of seizures
1383,2003,633.6,Treatment of Seizures and Epilepsy,and epilepsy of seizures treatment
1384,2006,2.5,mg/mL soln,mg ml soln
1385,2010,633.7,Neonatal Seizures,neonatal seizures
1386,2013,0.1,"mg/kg when used for acute treatment of seizures, and 0.05 mg/kg",0 05 acute and for kg mg of seizures treatment used when
1387,2013,633.8,Status Epilepticus,epilepticus status
1388,2015,0.1,"mg/kg up to maximum of 4 mg, may repeat in 5-­10 min",10 4 5 in kg maximum may mg min of repeat to up
1389,2015,0.1,mg/kg up to maximum of 5 mg,5 kg maximum mg of to up
1390,2015,0.2,"mg/kg up to 10 mg total dose, may repeat in 5-­10 min",10 5 dose in kg may mg min repeat to total up
1391,2015,0.2,mg/kg,kg mg
1392,2015,0.2,mg/kg,kg mg
1393,2015,0.5,mg/kg,kg mg
1394,2015,0.15,mg/kg up to a maximum total dose of 10 mg; may repeat in 5-­10 min,10 5 a dose in kg maximum may mg min of repeat to total up
1395,2016,633.9,Reflex Seizures (Stimulus-­Precipitated,precipitated reflex seizures stimulus
1396,2016,633.10,Nodding Syndrome,nodding syndrome
1397,2021,635.1,Migraine,migraine
1398,2024,12.5,mg,mg
1399,2024,2.5,mg,mg
1400,2024,2.5,mg,mg
1401,2024,0.5,mg/kg/24 hr,24 hr kg mg
1402,2025,0.15,mg/kg/IV; max,iv kg max mg
1403,2025,0.2,mg/kg IV; 10 mg,10 iv kg mg
1404,2025,0.5,mg/kg IV; 15 mg,15 iv kg mg
1405,2025,0.5,mg/dose every,dose every mg
1406,2025,1.0,mg/dose every 8,8 dose every mg
1407,2025,0.5,mg/spray,mg spray
1408,2026,16.8,± 2.0 years (minimum 11 years; maximum 21 years). OnabotulinumtoxinA injections improved disability scores (PedMIDAS) and,0 11 2 21 and disability improved injections maximum minimum onabotulinumtoxina pedmidas scores years
1409,2026,635.2,Secondary Headaches,headaches secondary
1410,2027,635.3,Tension-­Type Headaches,headaches tension type
1411,2027,636.1,Neurofibromatosis,neurofibromatosis
1412,2030,636.2,Tuberous Sclerosis,sclerosis tuberous
1413,2031,636.3,Sturge-­Weber Syndrome,sturge syndrome weber
1414,2032,636.4,Von Hippel-­Lindau Disease,disease hippel lindau von
1415,2032,636.5,Linear Nevus Sebaceous Syndrome,linear nevus sebaceous syndrome
1416,2032,636.6,PHACE Syndrome,phace syndrome
1417,2032,636.7,Incontinentia Pigmenti,incontinentia pigmenti
1418,2033,637.1,Ataxias,ataxias
1419,2038,637.2,"Chorea, Athetosis, and Tremor",and athetosis chorea tremor
1420,2041,637.3,Myoclonus,myoclonus
1421,2041,637.4,Dystonia,dystonia
1422,2044,637.7,Pantothenate kinase–associated neurodegeneration,associated kinase neurodegeneration pantothenate
1423,2044,637.20,and Figure 637.9.,637 9 and figure
1424,2045,638.1,Cerebral Palsy,cerebral palsy
1425,2049,638.2,Mitochondrial Encephalomyopathies,encephalomyopathies mitochondrial
1426,2051,638.6,"and 638.8. However, brain MRI rarely leads to a specific genetic",638 8 a and brain genetic however leads mri rarely specific to
1427,2051,638.3,Other Encephalopathies,encephalopathies other
1428,2052,638.4,Autoimmune Encephalitis,autoimmune encephalitis
1429,2056,639.1,Sphingolipidoses,sphingolipidoses
1430,2058,639.2,Neuronal Ceroid Lipofuscinoses,ceroid lipofuscinoses neuronal
1431,2058,639.3,Adrenoleukodystrophy,adrenoleukodystrophy
1432,2058,639.4,Sialidosis,sialidosis
1433,2059,639.5,Miscellaneous Neurodegenerative,miscellaneous neurodegenerative
1434,2062,640.1,Acute Disseminated,acute disseminated
1435,2063,640.2,Optic Neuritis,neuritis optic
1436,2064,640.3,Transverse Myelitis,myelitis transverse
1437,2066,640.4,Multiple Sclerosis,multiple sclerosis
1438,2067,640.5,Myelin Oligodendrocyte,myelin oligodendrocyte
1439,2069,640.6,Neuromyelitis Optica Spectrum,neuromyelitis optica spectrum
1440,2071,641.1,Arterial Ischemic Stroke,arterial ischemic stroke
1441,2073,641.4,and see Table 641.3). Cranial ultrasound frequently misses,3 641 and cranial frequently misses see table ultrasound
1442,2074,641.2,Cerebral Sinovenous Thrombosis,cerebral sinovenous thrombosis
1443,2075,641.3,Spinal Cord Lesions Associated with,associated cord lesions spinal with
1444,2075,641.4,Hemorrhagic Stroke,hemorrhagic stroke
1445,2077,641.5,Differential Diagnosis of Strokelike,diagnosis differential of strokelike
1446,2079,643.1,Acute Bacterial Meningitis Beyond,acute bacterial beyond meningitis
1447,2081,643.2,"and 643.3 and see Chapter 643.2). Focal infections of the CNS,",2 3 643 and chapter cns focal infections of see the
1448,2085,7.5,divided q8h,divided q8h
1449,2085,7.5,divided q8h,divided q8h
1450,2086,643.2,Viral Meningoencephalitis,meningoencephalitis viral
1451,2088,643.3,Eosinophilic Meningitis,eosinophilic meningitis
1452,2093,646.1,Tethered Cord,cord tethered
1453,2093,646.2,Diastematomyelia (Split-­Cord,cord diastematomyelia split
1454,2094,646.3,Syringomyelia,syringomyelia
1455,2095,646.4,Spinal Cord Tumors,cord spinal tumors
1456,2095,646.5,Spinal Arteriovenous Malformations,arteriovenous malformations spinal
1457,2102,648.1,Myotubular Myopathy (Centronuclear,centronuclear myopathy myotubular
1458,2103,648.5,distinguishes CNM from other congenital myopathies.,cnm congenital distinguishes from myopathies other
1459,2103,648.2,Congenital Muscle Fiber–Type,congenital fiber muscle type
1460,2104,648.3,Nemaline Rod Myopathy,myopathy nemaline rod
1461,2104,648.4,Core Myopathies,core myopathies
1462,2105,648.7,shows a family with a recessive RYR1 gene variant in the index,a family gene in index recessive ryr1 shows the variant with
1463,2106,648.5,Myofibrillar Myopathies,myofibrillar myopathies
1464,2107,648.6,Brain Malformations and Muscle,and brain malformations muscle
1465,2108,648.7,Amyoplasia,amyoplasia
1466,2108,648.8,Muscular Dysgenesis (Proteus,dysgenesis muscular proteus
1467,2108,648.9,Benign Congenital Hypotonia,benign congenital hypotonia
1468,2108,648.10,Arthrogryposis,arthrogryposis
1469,2112,649.1,Duchenne and Becker Muscular,and becker duchenne muscular
1470,2112,649.1,Duchenne and Becker Muscular,and becker duchenne muscular
1471,2116,649.2,Emery-­Dreifuss Muscular Dystrophy/,dreifuss dystrophy emery muscular
1472,2116,649.3,Myotonic Muscular Dystrophy,dystrophy muscular myotonic
1473,2118,649.4,Limb-­Girdle Muscular Dystrophies,dystrophies girdle limb muscular
1474,2119,649.5,Facioscapulohumeral Muscular,facioscapulohumeral muscular
1475,2120,649.6,Congenital Muscular Dystrophies,congenital dystrophies muscular
1476,2122,651.1,Periodic Paralyses and Other Muscle,and muscle other paralyses periodic
1477,2123,651.2,Malignant Hyperthermia,hyperthermia malignant
1478,2124,651.3,Glycogenoses,glycogenoses
1479,2124,651.4,Mitochondrial Myopathies,mitochondrial myopathies
1480,2126,651.5,Lipid Myopathies,lipid myopathies
1481,2126,651.6,Vitamin E Deficiency Myopathy,deficiency e myopathy vitamin
1482,2127,652.1,Myasthenia Gravis,gravis myasthenia
1483,2130,2.6,mg for oculomotor symptoms. Side effects include nausea and,and effects for include mg nausea oculomotor side symptoms
1484,2131,652.2,Spinal Muscular Atrophies,atrophies muscular spinal
1485,2135,652.3,Other Motor Neuron Diseases,diseases motor neuron other
1486,2136,653.1,Peroneal Muscular Atrophy,atrophy muscular peroneal
1487,2141,653.2,Peroneal Muscular Atrophy (Axonal,atrophy axonal muscular peroneal
1488,2141,653.3,Congenital Hypomyelinating,congenital hypomyelinating
1489,2141,653.4,Roussy-­Lévy Syndrome,lévy roussy syndrome
1490,2141,653.5,Refsum Disease (HMSN Type IV) and,and disease hmsn iv refsum type
1491,2141,653.6,Fabry Disease,disease fabry
1492,2142,653.7,Giant Axonal Neuropathy,axonal giant neuropathy
1493,2142,653.8,Hypermyelinating (Tomaculous),hypermyelinating tomaculous
1494,2143,653.9,Leukodystrophies,leukodystrophies
1495,2143,653.10,Congenital Hereditary Sensory Pain,congenital hereditary pain sensory
1496,2146,655.1,Familial Dysautonomia,dysautonomia familial
1497,2147,655.2,Other Autonomic Neuropathies,autonomic neuropathies other
1498,2161,663.9,and Table 663.4.,4 663 and table
1499,2166,665.3,"and 665.4). Initial treatment of dacryocystocele is usually conservative, involving massage/digital decompression of the lacrimal",4 665 and conservative dacryocystocele decompression digital initial involving is lacrimal massage of the treatment usually
1500,2192,677.1,Idiopathic Sudden Sensorineural,idiopathic sensorineural sudden
1501,2208,686.1,Cutaneous Manifestations of Systemic,cutaneous manifestations of systemic
1502,2212,686.2,Multisystem Medication Reactions,medication multisystem reactions
